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There are many promising pharmacological treatments for neurological disorders 
whose efficacies are limited by difficulties in delivering therapeutics to disease 
afflicted tissue. The work in this dissertation addresses some of the issues associated 
with neural drug delivery through three main investigative routes: development of new 
and more effective delivery devices, comprehension of drug transport mechanisms, 
and improvement in pre-clinical testing models for new therapeutics. A major focus of 
this work is convection enhanced delivery (CED). In CED, drugs are infused directly 
into tissue through a needle or catheter, and therefore are able to penetrate deeper into 
tissue than diffusion mediated delivery. A novel implantable microfluidic device was 
fabricated and characterized for chronic convection enhanced delivery protocols. The 
device consists of a flexible parylene microfluidic channel that is supported during 
tissue insertions by a biodegradable poly(DL-lactide-co-glycolide) scaffold. The 
device was able to reproducibly inject fluid into neural tissue with final infusate 
distributions that closely approximate delivery from an ideal point source. Also, real-
time studies of drug transport through tissue were carried out using 2-photon excited 
fluorescence microscopy to monitor the movement of fluorescent nanoparticles in the 
rat cortex during delivery via CED. We found that perivascular spaces can drastically 
affect the distribution of therapeutic constructs larger than approximately 50nm by 
providing a high permeability conduit for transport through neural tissue. Finally, a 
 new endovascular microcatheter was developed that allows for selective intra-arterial 
injections in the rat brain. The device consists of a 169µm outer-diameter polyimide 
tube that has laser machined fluid delivery side-ports in the distal tip. A 450µm 
diameter by 1mm long poly(dimethyl siloxane) cylinder is attached to the distal end of 
the catheter to block blood flow in the carotid artery, to simulate an ischemic stroke. 
This device shows great promise for testing intra-arterial delivery of novel 
therapeutics in rat models. 
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CHAPTER 1 
 
INTRODUCTION 
 
Many promising pharmacological treatments for neural diseases exist, but the 
efficacies of the therapies are often limited by the difficulty of delivering drugs to the 
central nervous system (CNS). A major obstacle in neural drug delivery is the blood 
brain barrier (BBB), which prevents large molecules from passing from the vascular 
system to the brain. Because of the BBB, achieving physiologically relevant doses of 
drugs in neural tissue with systemic delivery can require extremely high, sometimes 
toxic, doses. To overcome these difficulties new delivery methods which circumvent 
the BBB and deliver drugs directly to affected areas of the brain are being developed. 
In one such technique, a polymer containing the drug is implanted in the brain. 
Over time, either the polymer degrades (if it is bioresorbable), or the drug leaches 
from the polymer matrix, thereby releasing the encapsulated drug in a controlled 
manner at the desired site. This technique has been used to deliver 1,3-bis(2-
chloroethyl)-1-nitrosourea (BCNU) [1, 2], methotrexate [3], taxol [4], dexamethasone 
[5], NGF [6, 7], and other compounds of interest in CNS therapies [8]. Implantable 
drug-containing polymers can produce extremely high concentrations at the point of 
release, but because drug transport is mediated by diffusion, the concentration decays 
exponentially with distance away from the implant. When this is combined with the 
fact that agents delivered to the brain interstitium are subject to rapid elimination via 
permeation through the brain capillary wall or metabolism within brain tissue, the 
result is that drugs delivered in this manner rarely penetrate more than 1–3mm in the 
tissue [4, 6]. While this is sufficient for some treatments, many diseases require that 
the drugs penetrate farther into tissue. 
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To increase the drug penetration and improve the spatial distribution of agents 
delivered directly to the brain, researchers have employed convection enhanced 
delivery (CED) [9]. In this technique, a solution containing the drug is injected into 
the brain through a small needle or catheter (20–30 gauge, 300–900µm OD). 
Transport is then driven by pressure gradients rather than concentration gradients, and 
the drugs are able to penetrate farther into the tissue compared with diffusive delivery. 
Many compounds have been delivered in both animal and human experiments using 
CED. For example, the infusion of small molecules [9-11], proteins [12-14], growth 
factors [15, 16], and nucleotides [17] has been examined in animals, and 
chemotherapy drugs [18, 19], proteins [20-22], and viral vectors [23, 24] have been 
administered in clinical trials in human patients. 
Although CED shows promise for treating disorders of the central nervous 
system, many technological and biological issues still remain. Notably, the use of 
large needles or catheters causes significant tissue damage upon insertion [25], and 
can increase the extent of backflow for a given infusion rate [26]. In addition the tip of 
the needle can become occluded with tissue. Compounding these issues, neural tissue 
is a highly inhomogeneous, poroelastic medium, and therefore predicting the fate of 
infused compounds is extremely difficult. 
The work presented in this dissertation addresses some of the issues with CED 
in two ways: development of novel microfluidic delivery systems that might 
outperform traditional needles and catheters for CED protocols; and elucidating 
mechanisms of drug transport through tissue during CED infusions. 
Chapter 2 of this dissertation describes the design, fabrication, and 
characterization of a novel flexible microfluidic device for chronic CED applications. 
Experimental evidence suggests that flexible infusion devices may outperform 
traditional rigid needles and catheters in chronic infusions by decreasing the 
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mechanical mismatch between the implant and the tissue. This mismatch can cause 
micro-tearing of tissue in the area of the device tip which results in undesirable 
infusate distributions. To enable the device to be inserted into tissue a microfabricated 
insertion scaffold was designed. The scaffold supports the parylene channel during 
insertions, and then biodegrades in the tissue to leave the implanted device. This 
implantable system was characterized through in vitro and in vivo experiments, and 
was repeatedly able to deliver fluid to neural tissue, with final infusate distributions 
that closely approximate ideal infusions from a point source. 
Chapter 3 addresses a different issue associated with CED. Since CED will be 
best utilized to administer large therapeutics that do not readily cross the BBB, it is of 
vital importance to understand how these constructs move through neural tissue when 
delivered to reduce leakage of drug from diseased tissue into healthy areas of the 
brain. Infusions of liposomes, viral vectors, high molecular weight tracers, and 
nanoparticles to neural tissue were shown to localize in the perivascular spaces of 
blood vessels within the brain parenchyma. In this chapter, 2-photon excited 
fluorescence microscopy was used to monitor the distribution of fluorescent 
nanoparticles delivered to the cortex of rats via CED using microfluidic probes. This 
imaging technique permits studies on much finer temporal and spatial scales than can 
be achieved with other imaging modalities, such as MRI. The results of these studies 
show that for large particles which are hindered from easily passing through the 
extracellular matrix, perivascular spaces provide a high permeability path for transport 
through tissue. The transport of nanoparticles through perivascular spaces was size 
dependant. Larger nanoparticles (100nm nominal diameter) were not distributed 
throughout the tissue, and a higher fraction of the infused particles were restricted to 
the perivascular spaces and did not localize in the extracellular space. Similarly, 
perivascular spaces were the preferred path for smaller nanoparticles (24nm nominal 
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diameter), though these particles were not entirely excluded from the extracellular 
matrix and were able to pass through the bulk tissue when no perivascular spaces were 
present, even at relatively low flow rates. 
Chapter 4 summarizes efforts to develop a microfluidic device for intra-arterial 
selective injection. In this technique a catheter is passed into the carotid artery where it 
can inject drugs into different branches of the intracranial arteries. This procedure has 
been most widely used in the field of interventional neuro-radiology as a way to treat 
ischemic stroke, i.e. the intra-arterial injection of recombinant tissue plasminogen 
activator. Intra-arterial selective injection could also be used to deliver drugs that 
might protect brain cells from undergoing apoptosis after reestablishing blood flow in 
cases of ischemic stroke – known as selective intra-arterial neuro-protection. This 
chapter describes the fabrication and characterization of a novel endovascular 
microfluidic catheter of use in small animal trials of candidate drugs for selective 
intra-arterial neuro-protection. The microcatheter must be able to reversibly simulate 
an ischemic stroke, and selectively inject different branches of the intracranial arteries 
of the rat. The catheter was made from 169µm outer-diameter polyimide tubing that 
had fluid delivery side-ports laser machined in the distal tip. To simulate the occlusion 
of the carotid artery a 450µm outer-diameter by 1mm long PDMS cylinder was 
attached to the distal tip of the catheter. This microcatheter was tested in rats, and 
successfully replicated a reversible stroke, and selectively injected different branches 
of the intracranial arteries. 
 Finally, chapter 5 summarizes the salient findings of the work in this 
dissertation, and provides discussion of what the future work on these problems might 
entail.
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CHAPTER 2 
 
FLEXIBLE MICROFLUIDIC DEVICES SUPPORTED BY BIODEGRADABLE 
INSERTION SCAFFOLDS FOR CONVECTION ENHANCED NEURAL DRUG 
DELIVERY 
 
 
2.1 Introduction 
 
Convection enhanced delivery (CED) is a promising new technique for treating 
neurological disorders. In CED drugs are infused directly into tissue through a needle 
or catheter [9]. This technique circumvents the blood brain barrier and can achieve 
high local concentrations of drug with fewer side effects than with systemic delivery. 
Because many agents delivered directly to the brain are subject to rapid elimination 
from the interstitial space via permeation through the capillaries or metabolism within 
brain tissue [27], drugs delivered by diffusion from polymer implants or bolus 
injections are often only able to penetrate a small distance (approximately 1-3mm [4, 
6]) from the implant. Since drug transport in CED is driven by pressure gradients 
rather than diffusion along concentration gradients, drugs can penetrate to tissue that is 
much further from the delivery site. Many compounds have been delivered in both 
animal and human experiments using CED. For example, the infusion of small 
molecules [9-11], proteins [12-14], growth factors [15, 16], and nucleotides [17] has 
been examined in animals, and chemotherapy drugs [18, 19], proteins [20-22], and 
viral vectors [23, 24] have been administered in clinical trials in human patients. 
However, current CED protocols that use standard needles and catheters are 
not suitable for chronic applications because of problems with tissue damage upon 
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insertion, backflow along the needle path, occlusion of the needle tip, and the tissue’s 
foreign body response. Microfabricated devices can offer many advantages over 
standard needles. Primarily, their small size limits tissue damage [25] and backflow 
[26]. Also, it is possible to locate the fluidic outlet away from the leading edge of the 
device to reduce occlusion of the fluidic channel. Furthermore, with current 
microfabrication technology it is possible to create devices with features that are not 
available with standard needles, e.g. recording and stimulating electrodes, chemical 
and mechanical sensors that could allow the device to respond to changes in tissue 
physiology, and multi-channel fluidics for delivering different compounds in a 
controlled regimen.  
Several researchers have created microfluidic silicon probes for use in the 
brain. Although these devices moderate backflow and the initial tissue damage due to 
insertion [28-30], they may not be particularly well suited for chronic implantation as 
the brittle nature of silicon increases the risk of a probe breaking inside the tissue. In 
addition, silicon probes have been found to cause a significant foreign body response 
[25, 31].  
Researchers have shown that flexible catheters perform better than rigid 
catheters in chronic infusion studies in rats. Guarnieri et al [32] examined the effect of 
rigid and flexible catheters on the delivery of carboplatin and doxorubicin in both 
healthy and disease challenged rat brains, and found that the drug distributions 
delivered by the flexible catheters more closely approximated the theoretical ideal 
distribution from a point source than the distributions delivered by rigid catheters. 
They hypothesize that this difference is caused by micro-tearing in the area around the 
rigid catheters due to relative motion between the brain and the implant, which creates 
a high permeability path for fluid to escape the intended delivery area. Flexible 
catheters may be able move with the brain, thus eliminating micro-tearing and 
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maintaining the close contact between the device and the tissue required for controlled 
delivery. This suggests that in treatments that use CED for chronic applications, 
flexible catheters could outperform traditional rigid devices. The feasibility of long 
term CED protocols has already been examined in clinical trials. A phase I trial 
examining the effect of year long infusions of GDNF in Parkinson patients found that 
there were significant increases in dopamine storage in the putamen as a result of the 
treatment [33]. However, subsequent phase II trials failed to replicate the success of 
that study [34]. To determine why this trial failed, Salvatore and coworkers infused 
GDNF into the putamen of Rhesus monkeys for 7 days, and conlcuded that the trial 
had not been successful because the infusate localized around the tip of the catheter 
and did not distribute widely in the tissue [35]. This result may be due to microtearing 
of the tissue around the implanted device. The use of a more flexible infusion catheter 
may reduce these problems and improve the efficacy of the treatment. 
Another neurological disease that may benefit from the application of chronic 
CED protocols is the highly aggressive brain tumor glioblastoma multiforme. This is 
an infiltrative tumor with cells that migrate away from the main tumor mass into 
healthy tissue [36].  In this case, CED is used to infuse into the tissue after the main 
tumor has been resected [37].  It is also used as a xenograft model to test the 
effectiveness of new drugs under development [38-40].  In both of these cases, it 
would be useful to be able to deliver drugs repeatedly, based on tumor growth, at 
exactly the same location.  It is very difficult to reinsert a needle or catheter for 
repeated applications of a drug at precisely the same location in tissue for a variety of 
reasons, and even if this were achieved, each insertion leaves a needle track that 
affects subsequent infusions.  A chronically implantable device such as the one 
presented here is well-suited for repeated CED therapy. 
Although flexible polymer microfluidic devices may demonstrate better long-
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term biocompatibility than silicon probes, their low rigidity makes them difficult to 
insert into tissue. To create chronic drug delivery implants that combine the desirable 
traits of small size and low rigidity, we constructed flexible parylene microfluidic 
devices supported by rigid scaffolds from poly(DL-lactide-co-glycolide) (PLGA, a 
biodegradable polyester). These scaffolds brace the flexible parylene device during 
insertion, but then degrade to leave the fluidic device in place in the tissue. Parylene 
was used for the microfluidic probe because it has many desirable characteristics. It 
has excellent dielectric properties (making it suitable for insulating electronics on the 
devices), it can be deposited using chemical vapor deposition (CVD) in uniform and 
consistent layers, and it is biologically compatible (meeting FDA class VI 
requirements). PLGA products are widely used in biomedical engineering applications 
as resorbable sutures [41], orthopedic implants [42], microspheres for controlled drug 
delivery [43], and tissue engineering scaffolds [44]. PLGA structures are generally 
formed in two ways, through solvent removal techniques [45] and through thermal 
embossing, where the polymer is heated above its glass transition temperature and 
formed into the appropriate shape [46, 47]. In this work the flexible microfluidic 
devices were constructed using top-down microfabrication techniques on a silicon 
wafer, and the degradable scaffolds were formed by hot-embossing the PLGA in a 
poly(dimethysiloxane) (PDMS) mold. 
It has been found that PLGA structures display size-dependent degradation 
where larger structures undergo bulk degradation and smaller devices display only 
surface erosion [48]. As our scaffolds are close to the reported cut-off size, we 
examined the in vitro degradation time of the PLGA supports to determine how they 
degrade. We found that the scaffolds degrade with the manufacturers reported 
degradation time, which suggests that they undergo bulk degradation.  
The performance of the microfluidic devices was examined through infusions 
 9 
of dye into agarose gel brain phantoms and acute injections into the striatum of 
C57BL/6 mice. The devices were capable of both penetrating tissue and delivering 
fluid in a controlled and reproducible way. 
 
2.2 Materials and Methods 
 
2.2.1 Parylene Microfluidic Devices 
 
The flexible parylene devices were produced on a silicon wafer using standard MEMS 
fabrication techniques. A schematic of the fabrication procedure is shown in Figure 
2.1. A CF4 plasma was used to roughen the surface of a clean 100mm single side 
polished silicon wafer before an 8µm thick layer of parylene-C was deposited using 
chemical vapor deposition (PDS 2010 LabCoter, Specialty Coating Systems, 
Indianapolis IN). This layer formed the base of the fluidic device. Next, photoresist 
(Shipley 1045) was spun on the wafer to a depth of 11µm (the intended height of the 
channels). This initial layer of photoresist was then patterned using contact 
lithography. The remaining photoresist defined the inside of the channels. A second 
8µm thick film of parylene C was then deposited to form the top of the microfluidic 
device. Next, a 150nm thick aluminum etch mask was deposited via e-beam 
evaporation (Mark 50 E-beam evaporation system, CHA Industries, Fremont CA). 
This mask was then patterned with a second photolithography step, and the exposed 
aluminum was removed via a wet-etch. An oxygen RIE (PlasmaLab 80+ RIE system, 
Oxford Instruments, Oxfordshire, UK) was then used to etch through the parylene to 
the silicon wafer which defined the device body and opened the ends of the channels. 
Finally, the photoresist inside the channels was dissolved in acetone. The probes could 
then be easily peeled from the wafer to form free-standing parylene microfluidic 
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devices. A detailed fabrication description is presented in Appendix I. 
 
2.2.2 Biodegradable Insertion Scaffolds 
 
The PLGA insertion scaffolds were formed by hot-embossing PLGA granules in a 
poly(dimethylsiloxane) (PDMS) mold. To make the master mold, a silicon wafer was 
patterned using photolithography and selectively etched using a Bosch DRIE process 
(Unaxis SLR 770) to a depth of 200µm. This wafer was then silanized with 
tridecaflouro – 1,2,2 tetrahydrooctyl trichlorosilane before the PDMS mold was cast to 
prevent the mold from bonding to the master. To cast the PDMS mold, PDMS base 
and curing agent (Sylgard 184 silicone elastomer kit, Dow Corning, Midland MI) were 
mixed in a 10:1 weight ratio, and the mixture was thoroughly degassed. The mixture 
was then poured over the silicon master and cured at 70°C for three hours. When the 
mold had cured, it could be peeled from the master and used for hot-embossing. 
The scaffolds were formed using a method similar to that demonstrated by Yang et al 
[47]. A schematic of the hot embossing procedure is shown in Figure 2.2. Granules of 
PLGA (5050 DL 3.5A, Lakeshore Biomaterials, Birmingham AL) were placed on the 
mold and a second piece of non-patterned PDMS was placed on top. This sandwich 
was placed in a laboratory press with heated platens, heated to 150 – 160°C and 
pressed at approximately 3.5MPa for 5 – 10min. The assembly was cooled to below 
the glass transition temperature of the PLGA by circulating water through the platens. 
The sandwich was then disassembled, and the finished PLGA scaffolds could be 
cleanly removed from the mold. 
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Figure 2.1. Fabrication schematic for flexible parylene microfluidic devices. 
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2.2.3 Device Assembly and In Vitro characterization 
 
To connect the microfluidic device to external tubing, one of the probe shanks was 
inserted into a 7cm length of PEEK tubing (150µm ID, 360µm OD) (Upchurch 
Scientific, Oak Harbor WA) and sealed in place using a two-part epoxy (Epoxy 907, 
Miller-Stephenson, Danbury CT). The other end of the PEEK tubing was glued into 
the end of a borosilicate micropipette (1mm OD, 0.58mm ID) (World Precision 
Instruments Inc., Sarasota FL) using more epoxy. The parylene probe and PEEK 
tubing were fully primed with the fluid to be infused under vacuum, and then the 
micropipette was backfilled using a syringe with a 28 gauge MicroFil needle tip 
(World Precision Instruments Inc.). The micropipette served as the fluidic reservoir for 
the parylene device. The proximal end of the glass micropipette was connected to a 
programmable pressure injector (PM8000, World Precision Instruments Inc.) using a 
micro-electrode holder. To infuse fluid using the parylene device a constant pressure 
was applied to the fluidic reservoir in the micropipette via the pressure injector. The 
volumetric flow rate was determined by measuring the speed of the meniscus in the 
lumen of the micropipette. 
To attach the microfluidic device to the insertion scaffold a small drop (~15µl) 
of 5-min epoxy (Devcon, Danvers MA) was placed on the body of the scaffold and the 
primed microfluidic device was carefully laid on top under a stereoscope. The cured 
epoxy coupled the body of the scaffold to the body of the parylene device, leaving the 
shanks aligned but not connected. The shanks were then sealed together by briefly 
dipping them in dichloromethane. This treatment removes the highly permeable fluidic 
track between the two parts of the system. The device assembly was allowed to air dry 
for at least 15 min to ensure that all residual dichloromethane had evaporated. 
To allow the device to be inserted smoothly and reproducibly, the body of the 
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Figure 2.2. Fabrication schematic for hot embossing of PLGA insertion scaffolds. 
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scaffold/probe assembly was attached via double-sided adhesive tape to a custom 
made Delran block which was mounted on a micromanipulator. 
This scaffold/microfluidic assembly was tested in a 0.6wt % agarose gel brain 
phantom to verify that the scaffolds were capable of penetrating tissue and that the 
microfluidic channels remained patent. To examine the effect of dichloromethane 
treatment on the performance of the channels, the flow rates obtained for a range of 
driving pressures (6.9, 17.2, 34.5, 68.9, and 103.4 kPa) were compared before and 
after dichloromethane treatment. 
 
2.2.4 PLGA Scaffold Degradation Studies 
 
In vitro degradation studies were carried out to determine the degradation time of the 
insertion scaffolds. PLGA scaffolds were weighed and placed in 50mM HEPES buffer 
containing 10mM KCl and 0.1% wt/v NaN3 (pH 7.4) and incubated at 37°C. Samples 
were removed every third day, washed, lyophilized and examined for gravimetric 
weight loss and molecular weight loss using GPC. The pH of the buffer was monitored 
and replaced with fresh buffer if the acidic degradation products caused the pH to drop 
below 7.3. 
 
2.2.5 Acute In Vivo Infusions 
 
Five male C57BL/6 mice weighing between 22 and 25g were anesthetized by an 
intraperitoneal injection of ketamine/xylazine (0.1mg/10g mouse ketamine, 0.1mg/10g 
mouse xylazine). Animals were then secured in a stereotactic frame, and an incision 
was made in the skin along the dorsal midline of the skull. A small craniotomy (3mm 
diameter) was made over the left side of the exposed skull using a dental drill. The 
 15 
probe and attached scaffold were implanted using a micromanipulator 0.5mm anterior, 
2.5mm medioateral, and 3mm deep from bregma. The device was then left implanted 
for 2 min to allow the tissue to equilibrate before starting the infusion. Evan's Blue dye 
(2wt% in phosphate buffered saline) was infused using a starting infusion pressure of 
0.69kPa, and the infusion pressure was increased at a rate of 0.69kPa/30s to the final 
infusion pressure of 3.45kPa. After 1µl of dye had been injected, the infusion was 
stopped. The probe was left in the tissue for 2 min before being removed. The animal 
was removed from the stereotactic frame and immediately sacrificed via cardiac 
injection of urethane. The brain was then promptly extracted and frozen on dry ice. 
The frozen brain was sectioned into 20µm thick slices on a cryostat and every third 
slice was retained for imaging. All procedures were carried out in accordance with the 
Cornell University Institutional Animal Care and Use Committee guidelines and 
regulations. 
 
2.2.6 Image Analysis 
 
Tissue slices were imaged using a stereoscope and CCD camera. The captured RGB 
TIFF files were analyzed using ImageJ software (NIH, Bethesda MD) and a custom 
macro. The macro adjusted the contrast of the image, and split the RGB image into its 
constituent colors. The macro then took the red image, adjusted the contrast and 
converted the image to binary where the area stained with Evan’s Blue dye was white, 
and the rest of the image was black. Next, noise was removed from the image by 
replacing each pixel with the median value in its 3 × 3 neighborhood. Finally, the area 
of the white pixels was summed to get the area of the Evan’s Blue spot. The volume of 
distribution of the dye was calculated by summing the areas of distribution in each 
slice and multiplying the total by three times the slice thickness (to account for 
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discarded sections). 
 
2.3 Results 
 
2.3.1 Parylene Probes and Insertion Scaffolds 
 
The parylene microfluidic devices had an overall length of 10.3mm and a 2mm wide 
body for ease of handling. The insertable shank was 150µm wide and 3.225mm long 
(Figure 2.3). The devices were very flexible, and not rigid enough to penetrate tissue 
unaided (Figure 2.4). The microfluidic fluidic channel was 11.4µm high, 50µm wide, 
and had two openings at the inlet and outlet of the device to minimize occlusion 
(Figure 2.5). 
The hot embossing technique was capable of rapidly producing highly uniform 
insertion scaffolds. The scaffolds were measured under an optical microscope and 
were slightly larger (< 10%) than the original silicon master, most likely because of 
thermal expansion of the PDMS mold during the embossing process. Scanning 
electron micrographs of the scaffold shank and tip are shown in Figure 2.6. 
 
2.3.2 In Vitro Performance 
 
The fluidic devices were easily inserted into agarose gel phantoms. Also, the 
dichloromethane treatment used to seal the shanks of the scaffold and parylene device 
together had no effect on the flow characteristics of the device. We were able to infuse 
dye solutions into the brain phantoms with negligible backflow, and the observed 
distributions closely approximated the spherical distribution of an ideal point source.  
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Figure 2.3. Whitelight image showing finished parylene microfluidic devices before 
they are removed from the silicon wafer. 
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Figure 2.4. Photograph demonstrating the flexibility of the parylene devices. 
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Figure 2.5. Scanning electron micrograph of the tip of the flexible parylene device. 
Note the two channel openings. 
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Figure 2.6. Scanning electron micrographs showing the (A) insertable shank of the 
PLGA scaffold, and (B) the tip of the scaffold. Note the striations on the side of the 
device in (B). These are artifacts of the deep silicon etch used to define the master. 
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Figure 2.7 shows the results of an infusion of green food dye into a 0.6wt% agarose 
gel brain phantom at a flow rate of approximately 0.1µl/min. 
 
2.3.3 PLGA Scaffold Degradation Study 
 
The scaffolds used in the degradation study had an average initial weight of 2.37 ± 
0.41mg. The gravimetric weight loss as a function of time in the degradation buffer is 
shown in Figure 2.8. Figure 2.9 shows the molecular weight loss as a function of time 
and represents the extent of hydrolysis in the polyester backbone of the scaffolds. The 
gravimetric weight loss is a representation of the rate that the oligomers formed by 
hydroloysis of the PLGA backbone escape from the bulk of the structure. The 
scaffolds were almost 100% degraded after 27 days, but were observed to be swollen 
and had no rigidity after only 15 – 18 days. This was comparable with the 
manufacturer’s reported time (3 – 4 weeks), and indicates that these scaffolds are large 
enough to undergo bulk degradation rather than surface erosion. 
 
2.3.4 In Vivo Performance 
 
The parylene devices were used to infuse Evan’s Blue dye into the striatum of mice. 
The system was able to easily penetrate the tissue, and was able to deliver fluid in a 
reproducible distribution. The average flow rate obtained in the in vivo experiments 
was 0.09 ± 0.005µl/min (n = 5), at a driving pressure of 3.45kPa. 
 The volume of distribution (Vd) of the infusate was 5.17 ± 0.36mm3 (n = 5). 
Figure 2.10 shows an example of a brain section showing the distribution of Evan’s 
Blue and the corresponding binary image that was used to determine Vd. Figure 2.11 
shows a plot of the average area of the dye distribution in a section as a function of the 
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Figure 2.7. Photograph showing results of a test infusion of green food dye into a 
0.6wt% agarose gel brain phantom. 
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Figure 2.8. Gravimetric weight loss of PLGA scaffolds as a function of time. Error 
bars represent the standard deviation of three replicates. 
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Figure 2.9. Molecular weight loss of the PLGA scaffolds as a function of time. Error 
bars represent the standard deviation of three replicates. 
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Figure 2.10. Photograph of 20µm thick section of mouse brain tissue showing Evan’s 
Blue distribution (A), and the corresponding binary image that was used to calculate 
the volume of distribution as part of a series of sections (B). 
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Figure 2.11. The average area of dye distribution in each brain section as a function of 
the square of the distance from the infusion site. The shaded region represents the 
standard deviation of the data (n = 5). A line with slope pi is shown for reference. 
Areas of the plot with a slope equal to ±pi correspond to a region where the 
distribution is isotropic. Deviations from this slope indicate anisotropic distributions. 
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square of the distance from the infusion site. If the dye distribution volume can be 
represented as a body of revolution around an axis in the anterioposterior (AP) 
direction the data presented in Figure 2.11 should fall on a straight line. If the 
distribution was a perfect sphere, the slope of the line would have slope pi. Areas of 
the plot in Figure 2.11 with a slope equal to ±pi correspond to regions where the 
distribution is isotropic. Deviations from this slope indicate regions of anisotropic 
distribution.  
 
2.4 Discussion 
 
The parylene microfluidic devices in this study were capable of infusing fluids in 
mouse striatum at flow rates that are relevant for convection enhanced delivery. 
Although the in vivo infusion rate obtained in this study of 0.09µl/min is low when 
compared with flow rates used in CED studies in humans (e.g. 2-12µl/min, [18-24], it 
is comparable to flow rates used by other groups that have studied CED in mice [49]. 
In this study, our final flow rate was limited by backflow. As shown by Morrison et al 
[26], the length of backflow along the outside of a needle or catheter is directly 
proportional to the volumetric flow rate imposed and the radius of the infusion 
catheter. In our case, using a higher flow rate would have caused the backflow to 
extend further along the outside of the device where it would reach the corpus 
callosum. This is due to the small size of the striatum of C57BL/6 mice where the 
distance between the tip of the inserted parylene device and the corpus callosum is 
approximately 1.6mm [50]. A device with a longer shank (e.g. 5mm) could be used in 
rats at higher infusion rates without incurring backflow. In any event, these data show 
that the parylene/PLGA system is capable of delivering fluid in a controlled and 
reproducible way. The ratio of the volume distributed (Vd) to the volume infused (Vi) 
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was 5.17 (n = 5), with a standard deviation of 0.36 (6.9% of the mean). This value is 
close to the theoretical value obtained for the free volume of the tissue given a 
porosity of 0.2 [51], which suggests that the parylene/PLGA system distributed all of 
the infused fluid to the available extracellular space of the tissue. Furthermore, the 
results presented in Figure 2.11 show that the distribution volume closely 
approximates the ideal spherical distribution associated with infusion from a point 
source. 
 The slight increase in size of the scaffolds when compared with that of the 
original silicon master is likely due to thermal expansion and pressure induced 
deformation of the PDMS mold during hot embossing. This effect was also observed 
by Yang et al [47]. 
The degradation time of the scaffolds in this study was determined in vitro to 
be 27 days, which was consistent with the manufacturers reported value (3-4 weeks). 
Grayson et al [48] found that the sample size affected its degradation time; larger 
samples were subject to bulk degradation, which accelerated their degradation 
compared with smaller samples that degraded primarily by surface erosion. In our case 
the scaffolds were large enough to undergo bulk degradation and therefore exhibited 
the manufacturer’s reported degradation time.  
PLGA structures have a long history of use in controlled release drug delivery 
devices [52] and their release characteristics have been well characterized. The 
insertion scaffolds could easily be loaded with drugs that might influence the local 
tissue to improve the effectiveness of the CED protocol, e.g. the controlled release of 
dexamethasone to mediate inflammation [53, 54]. To date, we have successfully 
loaded the PLGA scaffolds with up to 15wt% dexamethasone to examine the effect of 
local diffusive release of drug on the chronic performance of the parylene devices. 
Also, the degradation time of the scaffolds could be readily adjusted by changing the 
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molecular weight of the PLGA, by changing the end group, or by changing the lactide 
to glycolide ratio. This, in turn, could be used to control the duration of any local 
controlled release, which makes this a promisingly tunable system. 
This study also shows that a flexible microdevice can be inserted into tissue 
using an external PLGA scaffold to stiffen the probe. The method presented here may 
be of use to researchers developing flexible neural electrodes for chronic applications. 
Takeuchi et al [55] used poly(ethylene glycol) (PEG) as a stiffening agent for flexible 
neural probes. In their technique a fluidic channel on the device is backfilled with 
molten PEG, which solidifies and stiffens the device enough to allow it to be inserted 
into tissue. The PEG then dissolves once the device is implanted. However, their 
devices were tested in the cortex of rats, so it is unclear whether the PEG is rigid 
enough to allow the devices to be inserted accurately into deep tissue structures. 
Furthermore, their method requires the implantable device to have a relatively large 
fluidic channel that can be backfilled with molten PEG. The use of an external PLGA 
scaffold would not require a fluidic channel if recording/stimulating electrodes were 
all that were needed, which would simplify the fabrication. Moreover, the 
dichloromethane application step is not required if infusions are not being performed, 
further simplifying the use of this system. 
 
2.5 Conclusions 
 
The results of this study show that it is possible to insert flexible polymeric devices 
into neurological tissue, and to use these devices to deliver fluid in a controlled and 
reproducible manner. This suggests that these devices could be suitable for use in 
chronic studies of convection enhanced delivery. Also, this is a straightforward 
technique, which could be easily used to implant other types of flexible neural 
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microprobes. 
 Although this system was conceived to exhibit improved chronic performance 
over conventional needles and catheters, characterizing and verifying that the system 
was capable of penetrating animal tissue and delivering fluid acutely and in a 
controlled way is a critical first step. 
 Future work on this system will compare the long term performance and 
biocompatibility of the parylene/PLGA system in chronic implants (with and without 
local diffusive delivery of therapeutics from the scaffolds), with those of silicon 
microprobes and conventional catheters. The devices will also be lengthened to permit 
their use in larger rodent models. 
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CHAPTER 3 
 
REAL TIME STUDIES OF PERIVASCULAR TRANSPORT OF 
NANOPARTICLES IN THE RAT CORTEX 
 
 
3.1 Introduction 
 
Convection enhanced delivery (CED) is a promising technique for delivering drugs 
that do not readily cross the blood brain barrier to neural tissue. In this technique, a 
solution containing the drug is injected into the brain using a small needle or catheter. 
The transport is driven by pressure gradients rather than concentration gradients (as is 
the case for diffusive delivery from an implant or other reservoir), and therefore the 
drugs are able to penetrate further into the tissue [9]. Since CED is most likely to be 
used to deliver therapeutics that are too large to cross the BBB, such as nanoparticles, 
liposomes, proteins, and viral vectors, it is essential to fully understand how these 
large constructs are transported through tissue. This is important in planning future 
CED protocols to minimize leakage of therapeutics away from diseased areas into 
healthy tissue. Unanticipated leakage can cause serious side-effects and also 
negatively impact the efficacy of the therapy, and has been one of the major 
drawbacks associated with CED in clinical trials [19]. The difficulty in controlling the 
infusate distribution is due to the inhomogeneous nature of brain tissue, which 
contains regions of varying permeability such as ventricles, white and gray matter, and 
necrotic areas within diseased tissue. CED studies of large therapeutics suggest that 
perivascular spaces may also influence the distribution of infusates by providing high 
permeability paths for fluid to move through the brain. 
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Perivascular spaces are extensions of the sub-arachnoid space that surround 
arterial and venous blood vessels which penetrate the brain down to the level of 
capillaries. For many years they have been studied for their role in the bulk flow of 
cerebrospinal fluid (CSF) through the brain and in solute transport through the central 
nervous system [56-61]. These studies demonstrated that tracers injected into the 
subarachnoid space distributed through the brain parenchyma via perivascular spaces. 
Cserr and Ostrach [62] examined how a bolus infusion of blue dextran in the 
striatum of a rat dispersed through the brain over 24 hours. They found that the dye 
spread over a greater distance than would be possible through pure diffusion, and 
noted that the tracer travelled along perivascular spaces away from the infusion site. 
Furthermore, they demonstrated that when edema around the insertion site was 
eliminated (by either administering an anti-inflamatory or waiting 7 days after 
inserting the cannula before infusion), that the dye remained localized around the 
insertion site and did not get widely distributed throughout the brain. This suggests 
that perivascular spaces act as conduits for elimination of excess fluid from the brain. 
Studies examining CED of liposomes and viral vectors have observed evidence 
of perivascular transport in rodents and primates [63-67]. Mamot and coworkers [66] 
co-infused liposomes and mannitol into rodent brains and intracranial and flank 
implanted xenograft tumors. During post-mortem histological examination they 
observed that the liposomes were distributed along the blood vessels of the tumors. 
Krauze et al [65] infused gadolinium and rhodamine loaded liposomes into the 
putamen of non-human primates while performing MRI and magnetic resonance 
angiography (MRA). Co-localizing the images from the MRI and MRA studies 
showed that the liposomes were travelling along large blood vessels in the brain, and 
histological examination showed that the liposomes were localized in the perivascular 
space of these vessels. Hadaczek and colleagues [64] infused viral vectors, fluorescent 
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liposomes, and BSA into the striatum of rats with high, low, and no heart-rate. They 
saw evidence of perivascular transport along vessels, and observed that heart rate was 
directly correlated to the final distribution volume of the infusates. They suggest that 
the passage of infusates through the brain may be aided by “perivascular pumping” 
through the perivascular spaces driven by pulsations of the vessel walls. 
Although these works demonstrated that large therapeutics tend to accumulate 
in the perivascular space, it is difficult to garner knowledge about the dynamics of 
how the drugs pass through tissue. Studies using MRI can track the distribution of 
paramagnetically labeled infusates in real time, but they lack the spatial resolution 
required for examining dynamic behavior for all but the largest blood vessels of the 
brain. In this study we used two-photon excited fluorescence (2PEF) microscopy to 
examine how nanoparticles are transported through the rat cortex during CED. This 
technique allowed us to monitor the nanoparticle distribution in real time, with 
micrometer-scale resolution.  
Two-photon excited fluorescence microscopy allows fluorescence imaging 
with intrinsic optical sectioning deep inside scattering specimens with diffraction-
limited resolution [68]. Briefly, a femtosecond laser pulse is tightly focused inside a 
specimen that has been labeled with a fluorescent molecule that does not linearly 
absorb at the wavelength of the femtosecond laser. At the laser focus, the laser 
intensity can become high enough to induce two-photon excitation of the fluorescent 
molecule. Because the excitation is nonlinear, the resulting fluorescence is only 
produced in the focal volume where the laser intensity is high. The fluorescence 
intensity is then recorded as the position of the laser focus is scanned throughout the 
specimen forming a three-dimensional map of the distribution of the fluorescent label. 
In addition, because photoexcitation occurs only at the laser focus, photobleaching of 
fluorescent dyes and photodamage to the sample are reduced significantly compared to 
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linear imaging techniques [69]. 
2PEF microscopy is well suited to in vivo imaging, especially deep inside 
highly scattering specimens. In widefield or confocal fluorescence microscopy, the 
fluorescence must be imaged to a camera or to a pinhole, respectively. Scattering of 
the fluorescence light leads to an unwanted background in widefield microscopy and 
to decreased signal strength in confocal microscopy. In 2PEF microscopy, however, 
because all the fluorescence originates from the focal volume, it need only be detected 
in order to contribute to the signal, not imaged to a camera or pinhole. Thus 
fluorescence that is scattered on the way to the detector still contributes to image 
formation, and does not produce an unwanted background. This tolerance to scattering 
of the fluorescence allows imaging deep into scattering samples. The imaging depth is 
ultimately limited by scattering of the femtosecond laser beam. In practice, one can 
image 500µm or more beneath the surface of typical tissues (brain, skin, kidney, etc) 
without loss of image resolution [68, 70-72]. 
In this study, we infused fluorescent nanoparticles into the cortex of rats using 
microfluidic delivery devices. During infusions, we captured 2PEF images at a fixed 
location in the brain which was a known distance from the tip of the microfluidic 
probe. By noting where in our imaging plane nanoparticles first appeared we could 
determine whether the particles were transported primarily through the perivascular 
spaces or through the extracellular space (ECS). Furthermore, because both the 
distance traveled by the nanoparticles and the elapsed time were measured, we were 
able to determine the primary transport mechanism by comparison to the characteristic 
times for convective and diffusive transport. We found that the nanoparticles were 
transported through the perivascular spaces much more readily than through the bulk 
extracellular space of the brain. These results show that delivery of large (50-150nm 
diameter) therapeutic constructs to neural tissue using CED requires careful 
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consideration of the vasculature of the target area to minimize the escape of 
therapeutics from the disease afflicted regions, and to maximize the effectiveness of 
the infused drug.  
 
3.2 Materials and Methods 
 
3.2.1 Nanoparticle Preparation 
 
Carboxylate-modified fluorescent nanoparticle stock solutions (24 and 100nm 
FluoSpheres, Invitrogen, Carlsbad CA) were sonicated for 15 minutes before being 
diluted to 0.02wt% solids in 1% BSA (Sigma-Aldrich, St. Loius MO) in phosphate 
buffered saline (approximately 1013 particles/ml and 1011 particles/ml for 24nm and 
100nm, respectively). The nanoparticle solutions were then gently rotated using a 
laboratory rotisserie at room temperature for 4 hours. This treatment reduced the 
surface charge of the nanoparticles and therefore reduced non-specific binding of the 
particles to the extra cellular matrix [73]. 
 The size and surface charge of the nanoparticles were determined before and 
after BSA incubation via dynamic light scattering and laser Doppler measurements of 
particle mobility under electrophoresis (Zetasizer Nano, Malvern Instruments Ltd., 
UK), respectively. 
 
3.2.2 Microfluidic Device Preparation 
 
Silicon based microfluidic devices were fabricated as previously described [30]. The 
devices had a 5mm long insertable shank with a 100×100µm cross-section. The 
microfluidic probes were attached to 150mm long borosilicate micropipettes (1mm 
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OD, 0.58mm ID) (World Precision Instruments Inc., Sarasota FL) with two-part epoxy 
(Epoxy 907, Miller-Stephenson, Danbury CT). The devices were backfilled with the 
nanoparticle solution under vacuum, before the glass capillary was filled via a syringe 
with a custom MicroFil tip (World Precision Instruments Inc., Sarasota FL). The 
micropipette served as the fluidic reservoir for the microfluidic device. The proximal 
end of the glass micropipette was connected to a programmable pressure injector 
(PM8000, World Precision Instruments Inc.) using a micro-electrode holder. To infuse 
fluid using the microfluidic device a constant pressure was applied to the fluidic 
reservoir in the micropipette via the pressure injector. 
 
3.2.3 In Vivo Nanoparticle Infusions 
 
Five male Sprague Dawley rats (weighing 283 - 370g) were anesthetized via intra-
peritoneal injection of 30wt% urethane in DI water (urethane dose of 150mg 
urethane/100g body weight). Animals were then secured in a stereotaxic frame and an 
incision was made in the skin along the dorsal midline to expose the skull. A large 
craniotomy (~1cm diameter) was opened in the left parietal bone using a dental drill 
and the dura was removed using a fine hook. The vasculature was labeled via tail vein 
injection of fluorescein isothiocyanate (FITC) conjugated to 2MD dextran or 
tetramethylrhodamine conjugated to 6kDa dextran. The tail vein injection 
fluorescently labels the blood serum, allowing the blood vessels of the cortex to be 
visualized under 2PEF. If red nanoparticles were used, the blood vessels were labeled 
with green FITC-dextran, and conversely, if green particles were used the vasculature 
was labeled with red tetramethylrhodamine-dextran. 
 Animals were then transferred to the stage of the 2PEF microscope, and 
microfluidic probes were inserted 1mm into the cortex at a downward angle of 15° 
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using a micromanipulator. The tissue was allowed to equilibrate for at least 2 mins 
before infusions were initiated. During this time, imaging stacks were collected in the 
dorsoventral direction to map the vasculature and to determine a suitable imaging 
location for monitoring the nanoparticle distribution during the infusion. The imaging 
location selected was the level directly above the probe that had the greatest number of 
vertically oriented blood vessels (i.e. penetrating arterioles and ascending venules) that 
intersected the imaging frame. A schematic of the experimental set-up is shown in 
Figure 3.1. Infusions were started at a driving pressure of 0.5psi, and the infusion 
pressure was increased at a rate of 0.1psi/30sec to a final pressure of 1psi. This 
resulted in a flow rate of approximately 0.1µl/min. 2PEF imaging frames were 
captured at 3.39 frames/second throughout the infusions and examined for the location 
of the first appearance of nanoparticle fluorescence (in perivascular spaces or in ECS). 
After an infusion was complete, the imaging area could be scanned through the tissue 
in three dimensions to map the final nanoparticle distribution (up to a maximum depth 
of approximately 700µm below the brain surface). 
2PEF images were taken on a microscope of local design using 100fs, 76MHz 
laser pulses from a titanium:sapphire oscillator (Mira-HP, Coherent, Santa Clara CA) 
pumped by a continuous wave laser (Verdi-V18, Coherent, Santa Clara CA). 
Excitation wavelengths were centered at 810nm and 850nm for yellow-green and red 
fluorescent nanoparticles respectively. Detection filters were 525/70nm and 
615/70nm.  Low magnification images were taken with a 0.2-NA, 4x air objective 
(Olympus). High magnification images used a 0.95NA, 20x water immersion 
objective (Olympus) with a 2mm working distance. 
All procedures were carried out in accordance with the Cornell University 
Institutional Animal Care and Use Committee guidelines and regulations. 
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Figure 3.1.  Experimental set-up for real-time 2-photon imaging of perivascular 
transport of nanoparticles. 
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3.3 Results and Discussion 
 
3.3.1 Nanoparticle Characterization 
 
In this study we used 2PEF microscopy to examine in real time how BSA coated 
polystyrene fluorescent nanoparticles are transported through rat cortex during CED. 
The measured diameter of the particles as received from the manufacturer were 
44.5±1.6nm and 134.8±0.6nm for the small (24nm nominal diameter) and large 
(100nm nominal diameter) respectively. This increase is possibly due to slight 
aggregation of the sample combined with the fact that dynamic light scattering 
measurements can be skewed by the presence of a few large particles. After incubation 
with BSA, the measured diameter of the particles increased to 62.1±3.9nm and 
152.3±2.7nm for the small and large nanoparticles respectively.  The average increase 
in diameter of the particles is 17.6nm, which is in good agreement with the 
hydrodynamic diameter of BSA (7.2nm [74]). The zeta potentials of the nanoparticles 
before BSA coating were -36.8±2.8mV and -38.6±3.6mV for the small and large 
particles respectively. After BSA coating the zeta potentials were -10.8±3.4mV for the 
small, and -11.4±2.5mV for the large particles. As anticipated, the surface charge was 
decreased by the presence of BSA. 
 
3.3.2  Nanoparticle transport in the rat cortex 
 
Microfluidic probes were inserted 1mm into the cortex of rats at a downward angle of 
approximately 15° and nanoparticle solutions were infused at a flowrate of 0.1µl/min. 
During infusions imaging frames were captured at a fixed level above the probe outlet 
but below the brain surface. We found that nanoparticles of both sizes preferentially  
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Table 3.1. Summary of the results of the nanoparticle infusions, giving the size of the 
particle infused, the distance from the probe tip to the imaging plane, and the time 
taken for the particles to appear in the imaging frame. 
 
Infusion Nominal particle 
size (nm)
Distance to imaging 
plane (µm)
Time to arrival at 
imaging plane (s)
1 24 243 13
2 24 290 200
3 24 220 14
4 24 360 30
5 24 92 No NP fluorescence seen
6 100 300 110
7 100 280 No NP fluorescence seen
 
 
traveled along perivascular spaces rather than through the ECS. Table 3.1 summarizes 
the experimental conditions for each infusion, giving the particle size, the distance 
from the probe outlet to the imaging plane, and the time taken for nanoparticles to 
reach the imaging plane. 
 
3.3.2.1 24nm nanoparticle transport 
 
 Five infusions of 24nm BSA coated nanoparticles were performed under real 
time monitoring via 2PEF microscopy (infusions 1-5, Table 3.1). In four of these 
infusions the first appearance of nanoparticles at the imaging plane was in the 
perivascular spaces of vessels (1-4, Table 3.1), followed by a gradual filling in of 
fluorescence in the extracellular space between the vessels (Figure 3.2). The 
nanoparticles did not spread into the tissue in a perpendicular direction to the 
perivascular space in an appreciable amount on the time scale of our experiments. The 
fluorescence in the perivascular space was primarily constrained around arterioles and  
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Figure 3.2. Time course showing transport of red fluorescent nanoparticles (24nm 
nominal diameter) through perivascular spaces during CED. Images were captured 
243µm above the outlet of the microfluidic device. Image A is at infusion time = 0s; B 
= 30s; C = 90s; D = 150s. Note appearance of nanoparticles around vessels in panel B, 
and gradual filling in of background ECS in panels C and D. 
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venules, with a small amount extending along capillaries for a short distance (~40-
50µm) after branching from larger vessels (Figure 3.3). 
 If we consider the infusion to be an ideal infusion into a porous medium from a 
point source, we can determine the characteristic time for the convective front of 
infused fluid to reach a radial distance from the point source, r, to be: 
 
3
3
4
rQtc
piφ
=
     (1) 
 
where, tc is the characteristic time for convection, Q is the flow rate of the infusion, 
and φ is the porosity of brain tissue (~0.2 [51]). Using this equation with a flow rate of 
0.1µl/min we find that the characteristic time for a convective front of fluid to reach 
the imaging plane of our experiments (a distance of 220-360µm) is between 5.4 and 
23.5 seconds. 
The characteristic time for a particle to diffuse a distance, r, through brain 
tissue can be determined from: 
 
*
2
D
r
td =      (2) 
 
where, td is the characteristic time for diffusion, and D* is the effective diffusion 
coefficient of the particle in the tissue. 
 
2* τ
DD =      (3) 
 
where, D is the diffusion coefficient of the particle in a free medium, and τ is the 
tortuosity of the extra cellular space of the brain (τ  ~ 2, [75, 76]). The diffusion 
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Figure 3.3. Image showing 24 nm nanoparticles in perivascular spaces around 
branching capillary. BSA-coated red nanoparticles were infused into the rat cortex, 
and the vasculature was labeled with fluorescein. The image shows the distribution of 
red fluorescent nanoparticle around a branching capillary (~10µm diameter). 
Nanoparticles extend for ~50µm along the capillary after branching from arteriole.
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coefficient of a particle in a free medium (e.g. water) can be estimated from the 
Stokes-Einstein equation: 
 
ηpi Hd
kTD
3
=      (4) 
 
where, k is the Boltzmann constant (1.38065×10-23 m2kgs-2K-1), T is the temperature in 
Kelvin (310 K), dH is the hydrodynamic diameter of the particle (24nm for the best 
possible case), and η is the viscosity of the free medium at the temperature T 
(6.9152×10-4 Pa.s [76]). Using these equations we can determine that the characteristic 
time required for a particle to reach our imaging plane from the outlet of the probe 
(220-360µm) through pure diffusion is between 90 and 241 minutes. 
 In our experiments, the time taken for fluorescence to appear in the imaging 
plane ranged from 13 to 200s (infusions 1-4, Table 3.1). From these data we can infer 
that the nanoparticles were transported through the tissue primarily via convection. 
The possible reasons that time for the nanoparticles to appear in vivo were longer than 
the characteristic convective times of 5.4 – 23.5 seconds are numerous. 
In the infusion that took 200s (infusion 2), post-infusion analysis showed that 
the majority of the fluid had backflowed along the insertion track of the microfluidic 
device due to a mechanical disturbance to the microfluidic probe, which resulted in 
tearing of the tissue in the area of the device tip. This meant that the bulk of the fluid 
was transported along the high permeability device track, leaving little driving 
pressure to force the fluid through the ECS to the perivascular space. The perivascular 
transport observed at the fixed imaging plane during the infusion was along a vessel 
that passed close to the microfluidic probe in a more ventral plane, and thereby 
intersected the backflowing nanoparticles. 
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 For the other infusions (1, 3, 4) the time taken for nanoparticles to appear at the 
imaging plane ranged from 13s for infusion 3 (220µm above probe outlet) to 30s for 
infusion 4 (360µm above probe) after the infusion began. In these cases the reasons 
for the longer time are most likely that the nanoparticles do not undergo ideal 
convective transport through the tissue, and that the perivascular spaces do not in 
general pass directly from probe outlet to imaging plane, but follow a longer and more 
circuitous path. Furthermore, the distance that the nanoparticles must travel through 
the ECS before reaching the perivascular space of the vessel that intersects the fixed 
imaging plane is different in each infusion, and unknown. The expression given above 
for the characteristic convection time (Equation 1) assumes that the volume of fluid 
infused occupies the free volume of the tissue. In the case of our infusions, it is very 
likely that the nanoparticles undergo hindered transport through the extracellular 
space, considering that their diameter is on the same order as the estimated pore size 
of the extracellular matrix (38 – 64nm [76]). Previous research in our group using 
these nanoparticles found that the ratio of the volume of nanoparticles distributed 
through the grey matter of the rat striatum to the volume of nanoparticle solution 
infused was 0.35 [73], rather than a value close to 5 as one would expect if all the 
infused fluid filled the extracellular space of the tissue. This suggests that the solid 
nanoparticles pass through the tissue more slowly than the fluid by a factor of 
approximately 14. If this is the case, it implies that the time taken for nanoparticles to 
reach the imaging plane by transport through the ECS would be on the order of 75 – 
330 seconds for distances of 220 – 360µm. These values are on the same time-scale as 
those observed during our infusions for the first appearance of nanoparticles in the 
ECS at our imaging plane. For example, in infusion 1 (Figure 3.2) the first appearance 
of nanoparticles at our fixed imaging plane (243µm above the channel outlet) occurred 
after approximately 55s. 
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In infusion 5, nanoparticles were seen to transport through the extra cellular 
space and no perivascular transport was observed in the imaging plane during the 
infusion. However, post-infusion imaging showed that nanoparticles had localized in 
perivascular spaces in a more dorsal plane than the imaging plane used during the 
infusion. This suggests that there were no highly permeable perivascular spaces in the 
fixed imaging plane used during the infusion, but that once the convective front of the 
nanoparticle distribution reached the perivascular spaces of larger vessels, these 
conduits of higher permeability then became the preferred path for nanoparticle 
transport. 
In infusion 4, we observed the nanoparticles traveling along a vessel that lay in 
the imaging plane at a distance of 360µm above the tip of the probe (Figure 3.4). This 
allowed us to measure the speed of the nanoparticle distribution along the vessel wall 
to be 0.026mm/s. Measuring the diameter of the blood vessel (0.03mm) and 
nanoparticle distribution (0.049mm) allows us to determine the cross sectional area of 
the perivascular space to be 1.18×10-3 mm2 (assuming that the perivascular space is a 
circular annulus around the vessel, and that the nanoparticle distribution occupies the 
entire perivascular space). Multiplying this area by the speed of the nanoparticle flow 
through the perivascular space gives a flow rate in the annulus of 1.84×10-3 µl/min. 
The velocity of the convective fluid front through a porous medium can be found 
from: 
 
( ) 24 r
Q
rv
piφ=      (5) 
 
where, v(r) is the velocity as a function of radial distance from a fluid source, Q is the 
volumetric flow rate of the fluid source, φ is the porosity of the tissue, and r is the  
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Figure 3.4. Time course showing transport of green fluorescent nanoparticles (24nm 
nominal diameter) along vessel in imaging plane. The vasculature is labeled with 
tetramethylrhodamine. Times represent duration of the infusion (A = 14.5s, B = 34.8s, 
C = 41.0s and D = 65.5s). Images were captured at a plane 360µm above the outlet of 
the microfluidic probe, 240µm below the surface of the brain. 
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radial distance from the fluid source. Substituting a flow rate of 0.1µl/min and a 
distance of 360µm we find that the speed of a convective fluid front passing through 
the ECS is approximately 0.005mm/s, which is five times slower than the speed of 
nanoparticle transport we observed in the perivascular space of a vessel this distance 
from the channel outlet. However, this increase is to be expected, since at this radial 
distance from the probe, the flow is travelling through the perivascular spaces and not 
the larger surface area for flow assumed above in Equation 5. This result shows that 
perivascular spaces can provide a route for rapid egress of large constructs from target 
tissue volumes.  
 
3.3.2.2 100nm nanoparticle transport 
 
In the case of the 100nm nominal diameter nanoparticles, two infusions were 
performed. In infusion 6 we saw nanoparticles reach the imaging plane (a distance of 
300µm) 110 seconds after the infusion was started, which was approximately 4 times 
longer than required for 24nm particles. In infusion 7, nanoparticles were not observed 
at the fixed imaging plane during the infusion, but post infusion analysis revealed that 
the particles followed the perivascular space of a vessel that passed close to the outlet 
of the microfluidic device but did not intersect the imaging frame at the level we were 
observing. In both cases, post-infusion imaging showed that the nanoparticles did not 
move through the ECS, and instead were constrained in the perivascular space of 
vessels (Figure 3.5). The long time taken for the nanoparticles to appear at the imaging 
plane is most likely due to the fact that the 100nm particles undergo greatly hindered 
transport through the ECS, since their diameter is approximately twice the average 
pore size of the extracellular matrix [76]. Once the nanoparticles reach the 
perivascular space there is little structure present to impede their motion [58]. This  
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Figure 3.5. Sections from a post-infusion stack in the dorsoventral direction, showing 
red fluorescent 100nm nanoparticles constrained in the perivascular space. Frame A is 
an optical section 50µm below the brain surface; B = 100µm; C = 150µm; D = 
200µm. Images show that the nanoparticles are distributed in the perivascular space of 
the vessel over a distance of several hundred micrometers. The outlet of the 
microfluidic device was 550µm below the brain surface. 
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suggests that for particles much larger than the pore size of the ECM, perivascular 
spaces might be even more significant paths for transport through the central nervous 
system than for smaller particles that undergo less hindered transport in the ECM. 
If a therapy involves delivering constructs that are going to undergo 
significantly hindered transport through the ECM to an area of the brain where 
perivascular spaces provide a high permeability path of egress to healthy tissue, it may 
be of use to increase the hydraulic permeability of the bulk extracellular space to 
reduce the likelihood that the particles will travel along the blood vessels to healthy 
tissue. This modification of the hydraulic permeability can be achieved through 
degrading or dilating the extra cellular matrix as demonstrated by Neeves and 
coworkers [73]. An alternative way to decrease the fraction of the therapeutic that 
escapes the target area through perivascular spaces would be to make the constructs 
smaller, thereby increasing the apparent permeability of the ECM seen by the 
particles. 
 
3.4 Conclusions 
 
In this study we used 2PEF microscopy to study the transport of fluorescent 
nanoparticles through the cortex of rats during convection enhanced delivery via 
microfluidic probes. The distributions of two different sizes of nanoparticles were 
examined. We observed that perivascular spaces in the area of the microfluidic device 
outlet can greatly affect the transport of the particles by providing high permeability 
conduits for fluid transport. 
 Furthermore, we noted that perivascular transport is dependent on the size of 
the particle involved. For smaller particles that can readily pass through the ECM the 
fraction of the infused particles that move through the perivascular spaces rather than 
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the ECS is lower than for large particles that undergo significantly hindered transport 
through the ECM. 
 From these results, it is clear that a thorough understanding of the vasculature 
of the target tissue and the physical properties of the construct being delivered are of 
critical importance in designing new CED protocols to reduce undesirable 
distributions and thereby maximize the effectiveness of the new therapies. 
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CHAPTER 4 
 
ENDOVASCULAR MICROCATHETER FOR SELECTIVE INTRA-ARTERIAL 
CEREBRAL INJECTION OF SMALL ANIMALS 
 
 
4.1  Introduction 
 
 It is estimated that 780,000 strokes occur in the United States every year. Of 
these, 600,000 are first attacks, and 180,000 are recurrent strokes. On average, 
someone in the United States suffers a stroke every 40 seconds. In terms of mortality, 
strokes accounted for 1 in every 16 deaths in the United States in 2004, which makes 
stroke the third leading cause of death behind heart disease and cancer. Stroke is also a 
major cause of long term disability. The American Heart Association estimates that 
the direct and indirect economic costs of stroke will total $65.5 billion in 2008 [77]. 
A stroke is a type of cardiovascular disease that occurs when part of the brain 
is starved of oxygen or nutrients due to a loss of blood flow. Brain cells in this blood 
deprived region die, resulting in neurological deficits or possibly death. There are two 
types of strokes: ischemic and hemorrhagic. Thirteen percent of stroke cases are 
hemorrhagic. These can be caused by leakage of blood from a vessel into the brain 
(intracerebral hemorrhage, 10% of total stroke cases), or by blood loss into the 
subarachnoid space between the arachnoid membrane and pia mater of the meninges 
(subarachnoid hemorrhage, accounting for 3% of total stroke incidences). Ischemic 
strokes account for the remaining 87% of all strokes and can be caused by thrombosis 
(formation of a clot in a blood vessel feeding the brain), embolism (migration of an 
obstruction from one part of the body into a vessel), or systemic hypoperfusion. This 
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work will focus on ischemic stroke. 
In an acute ischemic stroke there exists a region of brain tissue that is exposed 
to significantly reduced blood flow. This region is known as the core infarct, and is 
rendered nonviable within minutes of the arterial occlusion. Surrounding this core 
ischemic volume is a region of tissue known as the “ischemic penumbra” that suffers 
from reduced blood flow, but remains viable and could possibly be salvaged. 
Treatments for acute ischemic stroke focus on saving the ischemic penumbra by 
reestablishing blood flow to this volume, and studies show that early recanalization of 
the occluded vessel mitigates the long term neurological deficits associated with acute 
ischemic stroke [78, 79]. 
However, recanalization is not without risks, including: cerebral hemorrhage 
[80-82], reocclusion [83], late secondary ischemic injury (the delayed development of 
ischemic injury after initial signs of recovery) [84-86], and the continuation of 
oligemic zones to infarction despite reperfusion [87]. Two widely used techniques to 
achieve revascularization of the ischemic penumbra are described below. 
The most common therapy for ischemic stroke is the intravenous or 
intraarterial administration of recombinant tissue plasminogen activator (rt-PA).  
Mammalian blood has an intrinsic enzymatic system capable of dissolving blood clots 
known as the fibrinolytic enzyme system. This system contains a proenzyme, 
plasminogen, which can be converted to plasmin, a fibrin degrading enzyme [88]. rt-
PA is a serine protease that cleaves the arginine-valine bond of plasminogen, resulting 
in the active proteolytic enzyme plasmin. rt-PA is relatively clot-specific in that its 
activity is enhanced approximately 400-fold when bound to fibrin. However, this 
thrombolytic drug is generally only administered to the patient within 3 hours of the 
onset of the stroke due to the 10-fold increase in risk of intracranial hemorrhage 
associated with the treatment [89]. Studies have shown that the median delay between 
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stroke onset and arrival at a hospital is between 3-6 hours [77]. As a result, although 
this treatment is effective, only 2-3% of stroke patients receive it due to the limited 
window for administration [90]. 
In August 2004, the FDA approved a new device for treatment of ischemic 
strokes that has a longer therapeutic time window. The Mechanical Embolus Removal 
in Cerebral Ischemia (MERCI) device consists of three parts: the retriever, the 
microcatheter, and the balloon guide catheter (BGC). The retriever consists of a nitinol 
(a shape memory alloy of nickel and titanium) wire with 5 helical loops ranging in 
diameter from 2.8 to 1.1mm at its tip. 
To treat an ischemic stroke, the MERCI device is inserted into the femoral 
artery and fed through the vasculature to the site of the embolus where it ensnares the 
clot and completely removes the blockage from the patient’s body. Briefly, the 
microcatheter delivers the retriever to the clot in its straight configuration before being 
withdrawn to deploy the coil. The BGC is a larger catheter (2.1mm diameter) with an 
inflatable balloon at its tip. Once the location of the clot is identified using 
angiography, the BGC is inserted through a small incision in the femoral artery in the 
groin and is maneuvered up to the carotid artery in the neck. Next, the microcatheter 
and a guide wire are deployed through the BGC and placed just beyond the clot. The 
physician then deploys the retriever device to engage and ensnare the clot. Once the 
clot is captured, the BGC is inflated to temporarily arrest forward flow while the clot 
is being withdrawn. The embolus is then pulled into the BGC and completely out of 
the body. The balloon is deflated, and blood flow is restored [91]. 
However, even in the case that the MERCI device successfully removes a clot 
from the patient’s body, the ischemic penumbra may not survive. This is because 
reperfusion can cause cells in the ischemic penumbra to undergo delayed apoptosis 
due to the release of nitrous oxide and free-radicals as part of the ischemic cascade 
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[92]. After the MERCI device is deployed but before the embolus is removed, it is 
technically feasible to deliver pharmacologic neuroprotectants intraarterially to the 
ischemic territory through the microcatheter to mitigate the risks associated with 
recanalization. This is the concept of Intra-Arterial Selective Neuroprotection (IA-
SNP). 
Although many candidate neuroprotectant drugs exist [92], it is not possible to 
deliver them intra-arterially using the current standard small animal model for acute 
ischemic stroke. In this widely used model, the carotid artery of the animal is occluded 
using a thin filament that has a larger bulb on its distal tip. This bulb has to date been 
formed by melting the tip of a suture [93], or by coating the tip of a suture with 
silicone [94, 95]. This method of causing an infarct is minimally invasive, reversible, 
and effective. However, as it has no fluid delivery capabilities it is unable to 
accurately mimic the clinical possibility of selectively delivering neuroprotectants to 
the ischemic region preceding recanalization. 
The goal of this project was to develop a novel small animal model of ischemic 
stroke which could reversibly arrest blood flow to the brain to cause an infarct, and 
also deliver candidate neuroprotectants intra-arterially to the ischemic tissue prior to 
the re-establishment of blood flow. 
The design requirements of this small animal model are: (1) the catheter used 
to perfuse the ischemic region be small enough (170 – 200µm outer diameter) to pass 
through a constriction where the carotid artery enters the skull, and (2) the catheter 
must have side ports to deliver the prospective drugs. The main body of the novel IA-
SNP microcatheter was constructed from commercially available polyimide tubing, 
and fluid delivery side ports were formed by laser micromachining. A catheter of this 
size is too small to cause a significant occlusion in the artery. To address this, we 
attached a bulb that is flexible enough to pass through the constriction while still being 
 59 
large enough to simulate an embolus (350 – 450µm) to the distal tip of the catheter. 
We produced the flexible bulb from poly(dimethylsiloxane) (PDMS) because it has 
been widely characterized, its mechanical properties can be readily adjusted, and it can 
be cured into a wide range of shapes. 
Extensive in vivo testing of these catheters showed that they could 
reproducibly cause reversible strokes in rats with no intracranial hemorrhage, and that 
they could also selectively inject fluid into different branches of the rat internal carotid 
artery (ICA). These results show that the novel catheters could become a valuable tool 
in preclinical testing of intra-arterial delivery of novel therapeutics for neurological 
disease including, but not limited to, ischemic stroke. 
 
4.2  Materials and Methods 
 
4.2.1  Microcatheter Fabrication 
 
 The stroke-inducing catheters were constructed from two parts: an occluding poly-
dimethyl siloxane (PDMS) cylinder, and a polyimide fluid delivery catheter. A 
fabrication schematic is shown in Figure 4.1. 
To form PDMS cylinders Sylgard 184 base and curing agent (Dow Corning) 
were mixed in a 10:1 weight ratio and degassed in a vacuum chamber. Approximately 
2ml of this uncured PDMS was drawn into a 3ml luer-lock syringe attached to a 30G 
non-hypodermic needle. The PDMS was then injected into the lumen of a 5cm length 
of polyimide tubing (Small Parts Inc., Miramar FL). The tubing had an internal 
diameter that was the desired diameter of our occluding cylinder. After curing the 
PDMS in the tubing at 80°C for 2 hours, the PDMS cylinder was carefully removed 
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Figure 4.1. Schematic showing microcatheter fabrication procedure 
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from the tubing and cut into 1mm lengths using a razor blade and a specially designed 
cutting guide. 
The PDMS cylinders were placed standing up on a clean glass microscope 
slide and were treated for 3 seconds each with a hand-held corona treater (model 
BD20-AC, Electo-Technic Products Inc., Chicago IL). This treatment cleaves the 
methyl groups from the surface of the PDMS, exposing the reactive siloxane 
backbone. Using a syringe with a 30G needle, a drop of Bondit™ A-3 primer (Reltek 
LLC, Santa Rosa CA) was applied to each cylinder and allowed to air-dry for 15 
minutes. 
Meanwhile, the fluid delivery microcatheter was prepared by blocking one end 
of a 15cm length of polyimide tubing (049-I, Microlumen Inc., Tampa FL) with a 
small amount of epoxy (Epoxy 907, Miller-Stephenson, Danbury CT). The epoxy was 
cured at 80°C for 1 hour. The blocked end was then placed on a glass slide and treated 
with a drop of Bondit™ A-3 primer and allowed to air dry for 15 minutes. 
The PDMS cylinders were bonded to the blocked catheter tips using Bondit™ 
B45-TH epoxy (Reltek LLC, Santa Rosa CA). The catheter tips were dipped in mixed 
but uncured epoxy and were joined to the treated end of one of the PDMS cylinders 
under a stereoscope. The glued catheters were then placed upright in a specially 
designed frame in an oven at 100°C for 4 hours to cure the epoxy. If any of the 
cylinders slipped off the distal tip of a catheter during the cure, the tip was removed 
and the process was repeated. 
Next, the fluid delivery side-ports in the distal end of the catheter assemblies 
were laser machined using an excimer laser (Maestro 1000, Resonetics Inc., Nashua 
NH). Four pairs of holes were machined through the catheter at 1mm intervals from 
the occluding bulb and each pair was rotated by 90 degrees. Finally, polypropylene 
injection hubs (Small Parts Inc., Miramar FL) were glued to the proximal ends of the 
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catheters with epoxy (Epoxy 907, Miller-Stephenson, Danbury CT), which was cured 
at 80°C for 1 hour. 
Two types of microcatheter were produced. The first had no occluding PDMS 
bulb and was designated “µcath1”. The second, designated “µcath2”, had a 450µm 
diameter PDMS cylinder. 
 
4.2.2 In vivo Catheterization Procedure  
 
Sixteen adult male (270-330g) Sprague-Dawley rats were anesthetized using 
isofluorane gas (1-2% in 2 L O2) delivered via facemask. An incision was made in the 
scalp, and a transcranial laser Doppler probe was secured to the skull 3mm posterior 
and 5mm lateral to bregma to monitor blood flow in the cortex as the catheterization 
was performed. Next, the animal was turned to the supine position, and a 24-gauge tail 
vein catheter was placed. In non-survival animals (#1-2), 3000u/kg intravenous 
heparin was given in 2mL normal saline (NS). In survival animals (#3-16), 
intravenous tobramycin (antibiotic) was administered (180mg/kg in NS). The right 
ICA was exposed via a midline neck incision, the occipital artery sacrificed, the 
pterygopalatine artery permanently ligated, and an arteriotomy made in the right 
external carotid artery (ECA) as described previously [96]. A microcatheter loaded 
with 7-0 polyimide suture was introduced into the cervical ICA and advanced 22-
23mm (µcath1) or 18-20mm (µcath2) cephalad to the carotid bifurcation. With the 
catheter in place, a temporary ligature was placed around the cervical ICA. This 
surgical method and the imaging methods described below were reviewed and 
approved by the Weill-Cornell Medical College IACUC. 
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4.2.3 Angiographic and Perfusion Imaging 
 
After placement of µcath1, thoracotomy was performed on animal #1 and the right 
atrium of the heart was sectioned. Gadolinium diethylenetriamine pentaacetic acid 
(Gd-DTPA, Magnevist, Wayne, NJ) diluted 1:1 with NS was injected via the ICA 
microcatheter (300µL over 10 minutes). The brain was removed, incubated in 10% 
neutral buffered formalin (Sigma-Aldrich, St. Louis, MO) for 30 minutes, and 
transferred to a custom made 1.7cm diameter receiver coil. Ex vivo magnetic 
resonance imaging (MRI) was then performed using three-dimensional magnetization 
prepared rapid gradient echo (MP-RAGE).  
After placement of µcath1 animals #2-4 were transferred to the MR scanner 
where dynamic susceptibility contrast perfusion weighted imaging (DSC-MR) was 
performed before, during and after Gd-DTPA injection. Magnevist:saline (1:1) was 
delivered intracranially via manual injection with a 3mL syringe (Becton Dickinson) 
and a SmartPrep kit (TopSpins, Ann Arbor, MI) in series with µcath1. 
Magnevist:saline was injected over 20sec during dynamic gradient echo (GRE). After 
placement of µcath2, DSC-MR was performed on animals #5-7 using the same 
methods. 
After placement of µcath2, animal #8 was transferred to a microPET focus 220 
(CTI, Siemens, Malvern, PA). 20 µCi 18F-labeled deoxyfluoroglucose (18FDG) in 
10µL NS was injected via µcath2 over one minute. Five minutes later, a one-minute 
acquisition was performed. Five minutes later and with the animal in the same 
position, 412µCi in 206 µL was injected over 10sec via tail vein. Five minutes later, a 
second one-minute acquisition was performed. The animal was removed from the 
microPET system and transferred to the MR scanner, where axial T1-weighted images 
were acquired using a custom made 5cm diameter receiver coil. Animal #8 was 
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sacrificed immediately after MR acquisition. MicroPET images then were manually 
coregistered with raw axial T1 MR images and sagittal and coronal reformats 
according to the external contour of brain.  
 
4.2.4 Evaluation of Iatrogenic Injury of Catheterization 
 
Animals 9-16 were examined for catheterization related neurologic injury. In animals 
#9-12, µcath1 was advanced 22-23mm under continuous Doppler monitoring and 400 
µL NS was injected over 20 min. In animals #13-16, µcath2 was advanced 18-20mm 
and 200 µL NS was injected over 20 min. In all eight animals, the ICA microcatheter 
was removed within 25 minutes of placement, pulsatile, anterograde flow was re-
established in the cervical ICA and the neck incision closed. Forty-eight hours later, 
paw strength and the presence/absence of circular gait were tested. Animals were re-
anesthetized and transferred to the MR scanner. T2 weighted Fluid Attenuated 
Inversion Recovery (FLAIR) was performed using the previously described 5cm 
diameter solenoid receiver coil. Animals were sacrificed using intraperitoneal 
injection of high dose Nembutal (SleepAwayTM). Brains were removed, cut into 
100µm sections and stained with 1% triphenyl tetrachloride (TTC, Sigma), as 
previously described [97]. 
 
4.3 Results 
 
4.3.1 Microcatheter fabrication 
 
The finished microcatheters were constructed from two parts, a 15cm length of 
polyimide tubing and a PDMS cylinder that was attached to the distal end of the 
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polyimide tube (Figure 4.2). The polyimide tube had and external diameter of 169µm 
and had four pairs of laser machined side-ports to allow for fluid delivery. The side 
ports were 35µm in diameter, and each pair was spaced 1mm apart and rotated by 90° 
from the last. The PDMS cylinder was 1mm long and 450µm in diameter, and served 
to occlude the ICA terminus and its branches. The join between the PDMS cylinder 
and the end of the polyimide tubing was examined under both tension and torsion, and 
in all cases the PDMS cylinder ruptured before the adhesive join. This suggested that 
the bulbs would stay attached to the catheter during the catheterization procedures. 
 
4.3.2 In Vivo Microcatheter Characterization 
 
To characterize the microcatheters in vivo, 16 Sprague-Dawley rats were 
catheterized and fluid was injected intra-arterially via one of the two microcatheters. 
The territories of µcath1 and µcath2 injection were examined using magnetic 
resonance imaging (MRI). MRI, a non-invasive imaging technique, uses the 
interactions between the nuclei of atoms in a sample and external magnetic fields and 
radio waves to generate high quality images. Briefly, when the nuclei of atoms that 
have net spin (e.g. hydrogen nuclei) are placed in an external magnetic field, they line 
up along, and precess around the axis of the magnetic field at a specific frequency, 
known as the Larmor frequency. If a radio-frequency (RF) pulse at the Larmor 
frequency is applied to the sample, the nuclei can be flipped from being aligned with 
the external field to being aligned perpendicular to it. After the RF pulse is switched 
off the nuclei relax to their equilibrium state, and emit a radio-frequency free 
induction decay signal (FID). This signal forms the basis of the final image. By 
applying particular patterns of RF pulses and magnetic field gradients to the sample 
different features can be highlighted or suppressed in the final image. 
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Figure 4.2. Photograph showing microcatheter with attached 450µm PDMS cylinder. 
Note four pairs of side ports spaced 1mm apart. 
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  To validate the injected territory of µcath1, DSC-MR was acquired through a 
single axial plane in the rat forebrain 2mm posterior to bregma during and after Gd-
DTPA injection. Due to concentration effects, Gd-DTPA appears dark on this 
susceptibility-sensitive sequence. Injection via µcath1 during imaging demonstrated 
gadolinium perfusion of the right cerebral hemisphere (Figure 4.3) with sparing of the 
left. During the initial phases of injection via µcath1, the hypothalamus opacified in 
the same early phase as the rest of the hemisphere but washed out more slowly.  
A 450µm PDMS cylinder was affixed to the distal tip of µcath2 to occlude the 
ICA terminus and its branches, allowing selective injection of ipsilateral forebrain 
structures with sparing of cortex. The territory of injection of µcath2 was examined by 
performing perfusion MRI before, during, and after the injection of Gd-DTPA (a 
paramagnetic contrast agent) through the catheter while it was in position in the ICA. 
The results are shown in Figure 4.4. Due to concentration effects, Gd-DTPA again 
appears dark in these susceptibility-sensitive images. The different panels of the 
sequence demonstrate early and late arterial phases (A, B respectively), and early and 
late venous phases (C, D respectively) of the perfusion imaging opacification. 
 
18FDG injected through µcath2 perfused an ellipsoid region of the ventral 
forebrain (Figure 4.5). Using ear canal susceptibility effect as a landmark (Figure 4.5, 
panel D), the position of each axial image relative to bregma was determined for 
anatomic correlation [98]. The volume of rat brain occupied by >195µCi/mL was 
approximately 180µL, centered in the region of the hypothalamus (-1.3mm to -4.5mm 
relative to bregma) and tuber cinerum (-1.8 to -3.3). Of note, no activity was seen in 
the anterior choroidal territory (lateral thalamus), or substantia nigra (-6.3 to -4.8), 
which is supplied predominantly by the posterior circulation. 
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Figure 4.3. Injection of gadolinium into a single cerebral hemisphere. Approximately 
50-100µL of 1:1 Magnevist:NS was hand-injected via µcath1 over 20 sec. Axial T1 
GRE-MR images were acquired 4-5mm caudal to bregma at 0.0 (A), 11.2 (B), 22.4 
(C), 44.8 (D), 56.0 (E) and 112 sec (F) after gadolinium injection. 
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Figure 4.4. Time course of axial T1 GRE-MR images acquired 4-5mm caudal to 
bregma taken during a 20sec hand-injection of Magnevist:NS via µcath2. Images were 
acquired at 5.6 (A), 22.4 (B), 44.8 (C) and 56.0 sec (D) after the beginning of 
injection. (A) and (B) represent early and late arterial phases, respectively. (C) and (D) 
represent early and late venous phases. 
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Figure 4.5. Selective injection of 18FDG into hypothalamus. MicroPET data was 
acquired five minutes following injection of 20µCi 18FDG in 10µL NS via µcath2 
over one minute. Activity is represented by red (270µCi/mL), yellow (240µCi/mL), 
green (195µCi/mL) and blue (90µCi/mL). Manual co-registration was performed with 
2mm thick axial T1-weighted images and with coronal and sagittal reformats. Panel A 
is 1.0-0.8mm rostral to bregma, panels B-D are 1.0-1.2mm, 3.0-3.2mm 5.0-5.2 mm 
caudal to bregma, respectively. 
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4.3.3 Evaluation of Iatrogenic Injury of Catheterization 
 
Four animals were catheterized with µcath1 for 25 minutes, and monitored for 
changes in blood flow within the MCA territory. A transient flow reduction of 5-15% 
(monitored via Doppler probe) was observed for 2/4 animals. In both cases, the slight 
flow abnormality was first detected just as µcath1 crossed the skull base. In both 
animals, this small abnormality abated within five minutes. Four more animals were 
similarly examined using µcath2. 4/4 demonstrated a 40-73% reduction in flow within 
the MCA territory. In all four, the Doppler abnormality persisted until µcath2 was 
removed and the ICA revascularized. Figure 4.6 is a Doppler probe trace showing the 
effect of a catheterization with µcath2 on cortical blood flow. As the PDMS bulb of 
the catheter occludes the middle cerebral artery (MCA) the blood flow to the cortex 
drops to between 40% and 50% of baseline, indicating that the catheters are capable of 
simulating the effects of an embolus in the MCA. Forty-eight hours after 
microcatheter removal, no motor or visual field defect was detected on examination of 
these eight animals. There was no T2-bright lesion or extra-osseous region of 
susceptibility effect on MR examination. There was no intracranial hemorrhage on 
necropsy and no triphenyl tetrachloride lesion on histology to suggest infarction. 
 
4.4  Discussion 
 
The microcatheters were constructed from 169µm outer diameter polyimide tubing, 
with 25µm thick walls. Although larger polyimide tubing provides easier device 
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Figure 4.6. Doppler probe trace showing cortical blood flow in the middle cerebral 
artery (MCA) territory during MCA occlusion. The x-axis depicts time from an initial 
neck incision (t=0). The y-axis demonstrates cerebral blood flow in arbitrary units 
(blood perfusion units) within a 1-2mm3 volume of forebrain cortex measured by a 
laser Doppler probe embedded in the parietal bone. When the microcatheter is 
advanced to the MCA origin, cortical blood flow drops to 40-50% of baseline. 
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assembly, it was found to be too rigid to navigate the arteries of the neck and head of 
the rat without rupturing the fragile blood vessel walls. The polyimide tubing used in 
the final microcatheter was the smallest tubing in which we could reproducibly 
machine sufficiently large side-ports without failure of the catheter, and it was 
consistently able to be passed into the ICA without damaging the vessels. 
 The occluding bulb was fabricated from a PDMS cylinder. The cylinder was 
used as it provided more contact area between the bulb and the vessel wall compared 
with other geometries (e.g. a sphere). Furthermore, the use of a cylindrical bulb 
required that the PDMS be molded in the lumen of a piece of tubing of the desired 
final diameter. As a result, the final diameter of the occluding PDMS cylinders was 
highly reproducible and uniform.  
 The microcatheters could consistently inject specific territories of the brain 
with minimal contralateral leakage. µcath1 was able to inject the entire cerebral 
hemisphere through the anterior cerebral and middle cerebral arteries (ACA and 
MCA, respectively). The large occluding bulb of µcath2 prevented the injected fluid 
from passing into the ACA or MCA (Figure 4.7). In this case the catheter injected the 
anterior choroidal (AChA) and hypothalamic arteries (HTA) perfusing the 
hypothalamus and lateral thalamus without affecting the cortex. In the animal injected 
with 18FDG, fluid was seen in the hypothalamus but not in the territory of the AChA, 
however in the perfusion MR images fluid was observed in the AChA. Reconciling 
these findings hinges on the technical considerations. Acquisition of microPET images 
shown in Figure 4.5 was started five minutes after tracer injection. Given the rapid 
washout of the lateral thalamus visualized in Figure 4.4, it is not surprising that 
activity was absent in the lateral thalamus during delayed microPET image 
acquisition.  
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Figure 4.7. Intracranial arterial supply in rat with rostral oriented upward. Anterior 
(ACA), middle (MCA) and posterior (PCA) cerebral and hypothalamic (HTAs) and 
anterior choroidal (AChA) arteries are labeled (adapted from [99]). 
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These data illustrate that the use of two catheters with different distal 
geometries (bulb and no bulb) allow for the injection of different territories of the rat 
brain. This could be a major advantage of this technique in pre-clinical trials of intra-
arterial delivery of drugs for neurological disorders as it provides a new level of 
control over the specific areas of the brain that receive the therapy. 
 An important factor that must be evaluated before this system could be used to 
examine intra-arterial delivery of novel therapeutics in potentially valuable rodent 
models is the safety and neurological effect of the catheterization and injection 
procedure. Transcranial Doppler monitoring of the cortical blood flow during the 
catheterization showed that µcath1 (no distal bulb) had little to no effect on the blood 
flow in the MCA territory, and that any effect resolved itself within a few minutes. 
µcath2 (450µm PDMS cylinder) had a significant effect on the blood supplied to the 
ipsilateral MCA territory, and flow changes of 40-70% of baseline were observed. 
This reduced flow persisted until the microcatheter was removed from the ICA. 
Despite this, neither catheter was observed to cause any long term neurological deficit 
if left in place for up to 25 minutes. 
 
4.5 Conclusions 
 
These novel microcatheters permit the selective intra-arterial injection of specific 
regions of the rat brain. These devices hold promise for intra-arterial delivery of novel 
therapeutic agents, including but not limited to pharmacotherapy, viral vectors, 
nucleotide probes, radiolabeled ligands, nanoparticles or stem cells in rat models for 
neurological disease. Furthermore, if used in conjunction with the imaging techniques 
described above, valuable information about the real-time distribution of the injected 
drugs can be obtained. 
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 These catheters are capable of simulating an embolus, but to date the side-ports 
have not remained open long enough to allow for injection of potential 
neuroprotectants prior to recanalization due to clotting around the distal tip of the 
catheter. The next generation of catheters will attempt to overcome this issue by 
immobilizing an anti-clotting agent (e.g. heparin) on the surface of the catheters. 
 Future work on this system will involve more thorough characterization of the 
distributions and territories of the brain injected as a function of different injection 
parameters such as flowrate, and volume of delivery. 
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CHAPTER 5 
 
CONCLUSIONS AND FUTURE WORK 
 
 
This dissertation addresses some of the issues associated with neural drug delivery 
through three main investigative routes: development of new and more effective 
delivery devices, comprehension of drug transport mechanisms, and improvement in 
pre-clinical testing models for new therapeutics. Although this work does not fully 
resolve these issues, it provides a solid foundation for future research in these areas. 
This final chapter will summarize the findings presented in previous chapters, and 
discuss some of the potential work that could build on these results. 
 The design, fabrication and characterization of a novel, flexible microfluidic 
device for chronic CED applications were described in chapter 2. The flexible device 
was made from parylene, and was supported during insertions by a biodegradable 
PLGA scaffold which is designed to erode over time to leave only the parylene probe 
in the tissue. The microfluidic system was able to penetrate murine neural tissue, and 
effectively deliver fluid to the brain in a controlled way during acute infusions. The 
flexible nature of the device reduces the mechanical mismatch between the tissue and 
the implant, which should provide improved long term biocompatibility, and increase 
the effectiveness of therapeutics delivered using this system.  
 To date, this microfluidic system has been tested in acute implants in a mouse 
model, and although this is a critical first step in developing a chronic infusion device 
the next goal should be to examine the performance of the probe in chronic 
experiments. The chronic studies should examine the fluidic performance of the 
flexible probe compared to standard small gauge needles and silicon based 
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microfluidic devices. The studies should also examine the tissue response to the 
implants to evaluate whether the flexible device decreases glial scar formation and 
microtearing at the tissue-implant interface. It would also be valuable to examine 
whether using the PLGA scaffold to deliver an encapsulated drug (e.g. an anti-
inflammatory) as it degrades can positively affect the chronic performance of the 
system, as this is an advantageous capability which other systems do not provide. 
Finally, efforts to scale up this system should be undertaken, as the 3mm implantable 
length is not big enough to reach deep grey matter structures in rats, rabbits, etc. 
 Although this system was conceived as a chronic fluidic implant for CED, the 
use of an external biodegradable scaffold could be of tremendous interest to 
researchers wishing to perform long term electrical recording in deep structures of the 
central nervous system, as it allows for implants to be inserted several millimeters into 
tissue. Previous flexible microfabricated electrodes have been shown to penetrate only 
into the cortex, not to deeper structures [55, 100-102]. 
 Understanding the manner in which large drugs are transported through the 
brain during CED is of critical importance to designing protocols that will improve the 
spatial control of drug distributions, and minimize drug associated side-effects. 
Chapter 3 described the use of 2-photon excited fluorescence (2PEF) microscopy to 
study the motion of large particles through the brain during delivery via CED. We 
observed that perivascular spaces provide high permeability conduits for transport of 
large constructs (greater than approximately 50nm diameter). Furthermore, we saw 
that perivascular transport is size dependant. We showed that for smaller particles that 
can pass through the ECM, the fraction of the infused particles that move through the 
perivascular spaces rather than the ECS is lower than for large particles that undergo 
significantly hindered transport through the ECM. These results suggest that 
perivascular transport can have a significant effect on the fate of infused compounds, 
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and that the vasculature of the target area should be considered before performing 
CED to reduce unwanted drug distributions. 
 Further experiments need to be carried out to fully characterize the effect of 
how exclusion from the ECM promotes perivascular transport. This could be done by 
infusing a small fluorescent tracer that does not undergo hindered transport through 
the ECM while monitoring the distribution using 2PEF, and evaluating the fraction of 
the infused dye that localizes in the perivascular spaces. This might elucidate a cut-off 
hydrodynamic diameter of infusate where transport in perivascular spaces becomes 
significant. It would also be interesting to increase the porosity of the extracellular 
matrix through enzymatic degradation or osmolitic swelling to see if this could 
decrease perivascular transport of large particles in cases where this would be 
undesirable. 
 Chapter 4 outlined the fabrication and characterization a novel endovascular 
microcatheter for use in small animal models of selective intra-arterial 
neuroprotection. The microcatheter was made from 169µm polyimide tubing that had 
microfluidic side-ports laser machined in the end of the poyimide tubing for fluid 
delivery. Some catheters had a PDMS bulb attached to the distal tip to arrest blood 
flow in the artery. By using these different catheter designs (with and without distal 
bulbs), different areas of the rat brain could be unilaterally injected (whole hemisphere 
with no bulb, only deep brain structures with bulbed catheters). These devices hold 
promise for intra-arterial delivery of novel therapeutic agents, including but not 
limited to pharmacotherapy, viral vectors, nucleotide probes, radiolabeled ligands, 
nanoparticles or stem cells in rat models for neurological disease. 
 These catheters are capable of simulating an embolus, but to date the side-ports 
have not remained open long enough to allow for injection of potential 
neuroprotectants prior to recanalization due to clotting around the distal tip of the 
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catheter. It may be possible to overcome this problem by immobilizing an anti-clotting 
agent, such as heparin, on the surface of the device to keep the fluidic ports open 
during the multiple hour occlusions required to accurately simulate stroke conditions. 
 Future work on this system should involve more thorough characterization of 
the distributions and territories of the brain injected as a function of different injection 
parameters such as flow rate, and volume of delivery. 
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APPENDIX I 
 
DETAILED PARYLENE PROBE AND PLGA SCAFFOLD FABRICATION 
PROCEDURE 
 
The complete flexible implantable microfluidic device consists of two parts: a flexible 
parylene microfluidic component, and a rigid biodegradable PLGA scaffold. The 
scaffold supports the parylene device during insertion and degrades over time to leave 
just the parylene microfluidic device. The parylene microfluidic probe is produced 
using standard top-down microfabrication techniques, and the PLGA scaffold is 
formed by microembossing PLGA in a PDMS mold. This appendix will give an in 
depth description of the fabrication steps for each part of the device, and detail how to 
prepare the completed device for use. 
 
I. Parylene Microfabrication 
 
1. The first step in the fabrication procedure is to prepare the silicon 
wafers for the base layer of parylene. It’s best to work with batches of 
three wafers (100mm diameter, single side polished) for the process as 
this is the maximum capacity of many of the etching and deposition 
tools used. To clean the wafers of any organic residues, place them in 
the 70°C nanostrip bath for 15 mins, and wash them in the dump-rinse 
tank. Then dry the wafers in a spin-rinse drier. Finally, dehydrate the 
wafers on a 175°C hotplate for 3mins each. 
2. Next, etch the wafers in the PT-72 with a CF4 plasma for 1min to 
roughen the surface. Use program 8 at a power of 150W. 
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3. Place the wafers on glass microscope slides on the platen of the 
parylene deposition tool (CNF or NBTC). Raising the wafers off the 
platen ensures that the parylene coating wraps underneath the wafers. 
Also place Si wafer chips at the center, middle, and edge of the platen 
to determine the thickness of the parylene film. Deposit approximately 
5g of parylene. After the deposition check the parylene thickness by 
slicing the film on the Si chips with a razor blade and measuring the 
layer on the P-10 profilimeter. 
4. Roughen the surface of the parylene layer with a 30s, 100W O2 plasma 
in the Glenn. 
5. Place the wafers in a spin-coater and spin P-20 at 4000rpm. Next spin 
Shipley 1045 at 500 rev/s (5s, 1000 rev/s ramp), 800 rev/s (5s, 1000 
rev/s ramp), and 1000 rev/s (45s, 1000 rev/s ramp) using a dynamic 
pour. Soft bake the resist at 90°C for 3mins on a hot plate. 
6. Expose the wafers on the EV-620 using the channel mask at a dose of 
~250mJ/cm2. Develop in 300 MIF using a double-puddle technique, 
and hardbake the wafers at 90°C for 1min. 
7. Measure the resist profiles using the P-10 profilimeter. This recipe 
should give a channel height of approximately 10.7µm. 
8. Descum the wafers with another 30s, 100W O2 plasma in the Glenn, 
before depositing a second 5g film of parylene (as before). 
9. Roughen the surface of the parylene with another 30s, 100W O2 plasma 
in the Glenn before depositing 150nm of conformal Al using the NBTC 
evaporator. The conformal application ensures Al coverage of the 
sidewalls of the channels. 
10 Spin P-20 as before on the Al coated wafers. Then spin 1045 at 500 
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rev/s (5s, 750 rev/s ramp), 800 rev/s (5s, 750 rev/s ramp), and 1400 
rev/s (45s, 1000 rev/s ramp) using a dynamic pour. Softbake the wafers 
for 3min at 90°C . 
11. Expose the wafers on the EV-620 using the probe body mask at a dose 
of ~250mJ/cm2. Develop in 300 MIF using a double-puddle technique, 
and hardbake the wafers at 90°C for 1min. 
12. Etch the exposed Al in aluminum etch until visibly gone, plus 1min 
more. 
13. Etch the exposed parylene in an O2 plasma in the Oxford 81 (O2 Clean 
recipe, 150W) until the wafer is etched to the bare Si. Note: this step 
can take over 2hrs. 
14. If there is any photoresist remaining on the wafer strip it with acetone 
before stripping the remaining Al mask in aluminum etch. This etch 
will take longer than before as the Al has been thoroughly oxidized by 
the plasma. 
15. The final step is to clear the photoresist from the channels. It’s best to 
only clear the wafers as you need them. Place a wafer in a 6” 
evaporating dish with enough acetone to cover the wafer to a depth of 
~3mm, and cover. Leave the wafer for ~12hours. Once the channels are 
clear thoroughly rinse the wafer with IPA, and DI water. 
 
II. PLGA Microfabrication 
 
1. To produce the Si master for the hot-embossing procedure clean a 
100mm single side polished Si wafer as described above. 
2. Spin P-20 at 4000 rev/s for 40s, before spinning 1045 at 400 rev/s (5s, 
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750 rev/s ramp), 800 rev/s (5s, 750 rev/s ramp), and 1400 rev/s (45s, 
1000 rev/s ramp) using a dynamic pour. Soft bake the wafer at 90°C for 
3min. 
3. Expose the wafers on the EV-620 using the probe body mask at a dose 
of ~250mJ/cm2. Develop in 300 MIF using a double-puddle technique, 
and hardbake the wafers at 90°C for 1min. 
4. Clean the native oxide from the wafers with a 1min bath in 30:1 BOE. 
This step is crucial to avoid forming silicon grass during the Bosch 
Etch. 
5. Descum the wafer with a 30s, 100W O2 plasma in the Glenn before the 
deep silicon etch. 
6. Etch the wafer using the Bosch etcher (Unaxis) and the ‘1thru’ recipe. 
It takes roughly 550 or 600 loops to etch 200µm of Si using this recipe 
and mask, but regularly stop the etch to measure the actual depth of the 
etch. 
7. Strip the photoresist from the wafer, and place the wafer under vacuum 
with a drop of tridecaflouro-1,1,2,2 tetrahydroctyl trichlorosilane on a 
glass slide for 2-3 hours to silanize the wafer. If this step is skipped the 
PDMS will covalently bond with the wafer while curing and ruin the 
master. 
8. The mix approximately 55g of PDMS (10:1 base:curing agent by 
weight), and de-gas the mixture thoroughly until no large bubbles can 
be seen (usually 5-10 pump-down/vent steps). Tape the Si master into 
the bottom of a 150mm plastic petri dish (PDMS will bond to glass), 
and pour the uncured PDMS over it. De-gas the the wafer/PDMS again 
until no bubbles can be seen on the features of the Si master. Use shims 
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to level the petri dish and leave the PDMS overnight to cure partially. 
Once the PDMS is partially cured, place it in a 70°C oven for 2hrs to 
fully cure. 
9. Repeat this step using just a petri dish (no wafer) to form the 
unpatterned top of the mold. 
10. After the PDMS is cured, peel it from the petri dishes and cut it into 
appropriately sized squares (~1”) using a razor blade. If you try to do 
this while the PDMS is on the wafer in the dish you run the risk of 
cracking and ruining the master. 
11. Place a few granules of the PLGA you want to use in the outlines of the 
scaffolds in the mold bottom. You only need enough to fill the space of 
the mold, and it’s important to not use too much. Unfortunately, trial 
and error is the only way to determine the optimum amount of PLGA to 
add. 
12. Carefully place the unpatterned piece of PDMS on top and sandwich 
the assembly between two small squares of aluminum plate. Place this 
sandwich on the platen of the hydraulic press. 
13. Lightly close the platens of the press on the sandwich, and heat the 
assembly to above the glass transition temperature of the PLGA (this 
temperature will depend on the PLGA used). 
14. Press the sandwich using the fine-control mode of the press to a 
pressure of ~90psi, and press for at least 10mins. 
15. Cool the assembly back to room temperature by circulating cold water 
through the platens. Make sure to regularly check for ballooning or 
failure of the water supply tubing as the thermal cycling can damage 
the tubing. Also make sure that the platens are thoroughly cooled (i.e. 
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cold to the touch) before releasing the pressure on the PDMS mold. 
16.  Remove the mold, and carefully disassemble it. The PGLA scaffolds 
can now be removed using fine tweezers and some very gentle flexing 
of the mold, or with a piece of double-sided adhesive tape affixed to a 
flat surface such as a spatula tip. The scaffolds can be removed from 
the tape by rinsing them with IPA. 
 
III. Device Assembly and Use 
 
1. Glue a 7.5cm length of PEEK tubing (360µm OD, 150µm ID, 
Upchurch Scientific) into the lumen of a 580µm ID, 1mm OD 
borosilicate micropipette (World Precision Instruments Inc.) using 
Miller Stephenson 907 epoxy. Prepare the epoxy by mixing part A and 
part B in a 1:1 volume ratio (by eye) and stirring well. The finished 
epoxy should be a pale blue color. The PEEK tube should extend for no 
more than 2-3mm inside the lumen of the pipette. Leave the epoxy to 
cure overnight. 
2. To remove the parylene devices from the wafer, place a drop of IPA on 
the device you wish to remove. With the corner of a razor blade gently 
lift the body of the probe from the wafer. It’s best to work slowly, and 
hold the blade at a very shallow angle. Slide the corner of the blade 
under the corner of the handling tab and work along the length of the 
probe body gently lifting the device from the wafer. The IPA should 
help to smooth the process, and if all goes well the device should float 
off the wafer in the IPA. 
3. Next, use fine forceps and a stereoscope to remove the four tabs of the 
 87 
fluidic channels that extend from the channel openings. 
4. Insert one shank of the parylene device into the open end of the PEEK 
tubing under stereo-magnification. Use an anti-static gun to eliminate 
static charges on the tubing and device. 
5. Use a small sliver of plastic or wood to apply a very small amount 
Miller Stephenson 907 epoxy to glue the device in the tubing. Use the 
bare minimum amount of epoxy required to get a complete seal around 
the device. Use an anti-static gun if it becomes difficult to cleanly apply 
the epoxy to the join. 
6. Use a 1ml pipette tip inside a pipette-tip box to hold the glass 
micropipette upright while the epoxy cures. Cure the epoxy in an 80°C 
oven for 1-2 hours. 
7. Connect the finished devices to the programmable pressure injector 
using a 1mm electrode holder. Test the devices by passing air through 
them while the tip is submerged in water. Bubbles mean that the 
channels are patent. 
8. To prime the devices, connect them to the small vacuum pump using a 
microelectrode holder and some Teflon tubing. Submerge the entire 
parylene probe in the solution to be used, and back-fill the PEEK 
tubing and ~5mm of the glass micropipette by drawing a vacuum. 
9. After the PEEK tubing has been filled use a 1ml syringe with a 28G 
microfil tip to fill the rest of the glass pipette from the open end. Be 
careful not to introduce bubbles to the lumen of the pipette. 
10. To attach the microfluidic device to the insertion scaffold apply a small 
drop (~15µl) of 5-min epoxy (Devcon, Danvers MA) to the body of the 
scaffold, and carefully lay the primed microfluidic device on top under 
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a stereoscope. The epoxy couples the body of the scaffold to the body 
of the parylene device, leaving the shanks aligned but not connected. 
The shanks can be sealed together by briefly (<0.5s) dipping them in 
dichloromethane. This treatment removes the highly permeable fluidic 
track between the two parts of the system. Allow the assembly to air 
dry for at least 15 min to ensure that all residual dichloromethane has 
evaporated. 
11. Next, use double-sided adhesive tape to attach the body of the 
scaffold/probe assembly to a custom made Delran block which can be 
mounted on a micromanipulator. This is the final arrangement used for 
inserting the device into tissue or gels. 
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APPENDIX II 
 
DETAILED ENDOVASCULAR MICROCATHETER FABRICATION 
PROCEDURE 
 
I. PDMS Cylinder Preparation 
 
1. Prepare approximately 2g of PDMS (Sylgard 184) by mixing base and 
curing agent in a 10:1 weight ratio. Mix them in a disposable dish and 
use plenty of paper towels to wipe down everything to avoid getting 
PDMS everywhere. Degas the PDMS in a vacuum chamber to 
eliminate any large air bubbles. 
2. Draw the PDMS into a 3cc syringe with a luer lock. Pour a small 
amount of PDMS into the hub of a 30G needle (non-hypodermic, 
Smallparts Inc.) to prime the hub. Affix the needle to the syringe 
making sure to eliminate any air bubbles between the hub and the 
needle. 
3. Cut polyimide (PI) tubing with the same internal diameter as the 
desired external diameter of the PDMS cylinders to approximately 5cm 
lengths. Inject the uncured PDMS from the syringe into the PI tubing, 
leaving approximately 3-5mm of air space at each end of the tube. 
4. Put the PI tubes in the oven at 80°C for 2 hours to cure the PDMS. 
Cut the PI tubes containing PDMS in half. Carefully split the ends of 
the PI tube with the air space using a razor blade. Peel away the split PI 
tubing using forceps to expose the PDMS inside. It’s best to use the 
stereoscope for this stage, and be careful not to kink the PI tubing while 
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you dissect it. Once 1-2mm of the PDMS is exposed, grab it with a 
forceps and gently pull it from the PI tube. You need to be careful to 
pull the PDMS without twisting or bending it too much. Also, it’s best 
not to try to extract the PDMS in one go; it helps to release the tension 
on the PDMS so that the interface between the PDMS and the PI tube 
can relax, and then reapply tension. If you do this stage carefully, it 
should be possible to remove intact PDMS cylinders from the PI 
tubing. 
5. Examine the PDMS cylinder under the stereoscope, and cut away the 
end that was used for pulling it from the PI tube. Next, affix the PDMS 
cylinder to the cutting guide using double sided tape. Be careful to 
align the cylinder perpendicularly to the cutting guide; use the anti-
static gun if static charges make the PDMS jump around. Use the 
sliding guide and a razor blade to cut the cylinder into 1mm lengths. 
Cut ~15% more cylinders than catheters you hope to make to account 
for losses in the rest of the fabrication steps. 
6. Using extra fine tipped forceps, place the PDMS cylinders standing on 
their edges on a clean glass slide, distributing them evenly over the area 
of the slide. Plasma-clean the top surface of the cylinders using the 
handheld corona treater (Electro-Technic Products, Inc.). Use the 
straight wire electrode, and hold the tip ~5mm above the surface of the 
cylinder for 2 seconds. If you plasma treat the cylinders for any longer, 
the PDMS will be damaged and weakened. 
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II. Polyimide Catheter Preparation 
 
1. Cut 12” pieces of PI tubing (from MicroLumen) into 6” lengths. Ensure 
that the cut is perpendicular to the axial length of the tubing. 
2. Prepare Miller Stephenson 907 epoxy by mixing part A and part B in a 
1:1 volume ratio (by eye) and stirring well. The finished epoxy should 
be a pale blue color. 
3. Barely touch the original factory-cut end of the 6” section of PI tubing 
into the epoxy, just barely cover the end of the catheter. Wipe the 
excess epoxy from the tube with a kimwipe. Inspect the end of the tube 
to ensure that it is blocked. The ideal thickness of blockage is between 
1 and 1.5 times the ID of the catheter. 
4. Place the blocked catheters into glass capillaries, inside 1ml pipette tips, 
in a pipette tip box. This keeps the catheters straight and upright while 
they cure. 
5. Cure the epoxy in an oven at 80°C for 1 hour. 
 
III. Gluing - this step must be carried out immediately after plasma treatment 
of the PDMS cylinders 
 
1. Affix a 30G non-hypodermic needle to the 5ml syringe of Bondit™ A-
3 primer. This is available as a special order from McMaster-Carr, with 
a lead-time of 4-6 weeks. 
2. Dispense 1 small drop of primer onto the primed surface of the PDMS 
cylinders. Make sure that the cylinders stay upright during this process 
so that you know which end has been treated. Allow the primer to air 
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dry for 15 minutes. 
3. Lay the catheters so that the blocked distal ends lay on glass slides, and 
again apply a small drop of primer to each catheter tip, and allow the 
primer to air dry for 15 minutes. 
4. Next, prepare the epoxy for the gluing. Place the cartridge of Bondit™ 
B45-TH epoxy in the dispensing gun, and affix the 2:1 plunger. 
Squeeze out a small amount of epoxy (~3cm disc) and mix well. 
5. Once the primer has dried, barely dip the distal tip of the catheter into 
the epoxy and examine the coverage under the stereoscope. If you 
apply too little epoxy the PDMS bulbs will fall off, and if you apply too 
much epoxy surface tension effects will drag the cylinders off the 
catheter tips during the curing process. A good guideline is to see a 
small hemisphere of epoxy on the catheter tip with no epoxy on the 
sidewalls of the catheter. 
6. While holding the catheter with epoxy in one pair of forceps, pick up a 
PDMS cylinder from the glass slide using some extra fine forceps. 
Make sure to keep track of which end has been treated, and align that 
end with the distal tip of the catheter. Lightly touch the two ends 
together, and the PDMS cylinder should stick to the catheter tip. If all 
has gone well, and your hands are steady, the two pieces should form a 
straight line. If the PDMS cylinder is askew, gentle nudges with a 
forceps can sometimes straighten it. However, it is occasionally 
necessary to repeat the gluing step with a new cylinder. 
7. Once you are satisfied with the alignment of the PDMS cylinder 
carefully place the catheter in the capillary/pipette tip holder, and repeat 
for the rest of the batch. Do a final inspection of the catheter tips to 
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make sure none have slipped off, and carefully place the catheters in 
the oven. Cure the epoxy at 100°C for 4 hours. 
8. Remove the catheters from the oven and inspect them to make sure that 
the PDMS cylinders did not slip during the cure. If they did, cut off the 
tips with a razor blade, and repeat the blocking, priming, and gluing 
steps with new cylinders. 
 
IV. Laser Micromachining - refer to laser instructions for operating 
procedure 
 
1. Lay the catheters on some double sided tape in the bottom of a 150mm 
Petri dish. Place the catheters so that the most distal 6mm are hanging 
off the end of the tape, and align the catheters as closely to 
perpendicular to the tape as possible. This will simplify the laser 
machining. 
2. Cut a small piece (~1.5 cm) of PI tubing from the proximal end of one 
of the catheters, and place it on the tape. This will be used to focus the 
laser. 
3. Warm up the laser as per the operating instruction. Transfer the double 
sided tape with the catheters to the silicon wafer from the stage of the 
laser, and locate the focusing PI tubing. Focus the laser and replace the 
focusing mask with the #20.5 aperture. This gives a circular spot of 
approximately 35µm diameter. 
4. I have found that the following parameters work well for machining 
049-I tubing: 
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Energy (mJ) 100-
110 
# of Pulses 1000 
Pulse Rate 
(pps) 
75 
Aperture 20.5 
 
5. Test the parameters on the focusing tube to make sure that they are 
suitable, and move on to the catheters. Locate the distal plug of epoxy 
that blocks the catheter, and move 100µm proximally from the edge. 
This serves as your zero reference on each catheter. Machine the first 
pair of holes through the catheter here. Move 2mm proximally along 
the catheter and machine the second pair of holes. Repeat this for all 
catheters. 
6. Remove the catheters from the laser, and rotate each catheter 90° using 
some forceps and return them to the laser stage. Repeat the machining 
as before, but this time step off 1mm from the zero mark (100µm 
proximal from epoxy edge) to machine the first pair of holes. Again, 
move 2mm proximally and machine the final pair of holes. Repeat this 
for each catheter. Each catheter should now have four pairs of holes 
spaced 1mm apart, and each successive pair should be rotated by 90° 
from the last. 
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V. Finishing and Packaging 
 
1. Place the proximal ends of the catheters into polypropylene injection 
hubs (27-30G, Smallparts Inc.). Ensure that the proximal tip of the 
catheter extends to the end of the hub so that it will be easy to suture-
load the finished catheters. 
2. Glue the catheters in place using Miller Stephenson 907 epoxy 
(prepared as before). Use a small sliver of plastic or wood to apply the 
epoxy around the base of the catheter. Use the anti-static gun if it 
becomes difficult to cleanly apply the epoxy to the hub. Try to fill the 
reservoir at the base with epoxy to ensure a good seal. 
3. Cure the epoxy either overnight, or in the oven at 80°C for 1 hour. 
 
Notes 
 
1. Handling these catheters during the fabrication without damaging them 
takes practice, but the correct forceps helps immensely. When picking 
up the PI catheter tubing it is best to use some broad tipped forceps that 
don’t require much closing pressure. This minimizes the chances that 
the catheters will be crushed or kinked by the handling. 
2. For handling the PDMS cylinders it is best to use some extra fine 
tipped forceps that allow you to pick up the 1mm cylinders cleanly. 
When carrying out the gluing step, it is best not actually hold the 
PDMS cylinder. Pick up the cylinder, gently open the forceps and the 
cylinder will stick to one of the forceps tips. This will make it easier to 
cleanly attach the cylinder to the catheter tip. 
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